Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

overall POS N
survival POS N
was POS N
similar. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

overall POS N
survival POS N
was POS N
similar. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

overall POS N
survival POS N
was POS N
similar. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

overall POS N
survival POS N
was POS N
similar. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

overall POS N
survival POS N
was POS N
similar. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

overall POS N
survival POS N
was POS N
similar. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

overall POS N
survival POS N
was POS N
similar. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

overall POS N
survival POS N
was POS N
similar. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

This POS N
randomized POS N
controlled POS N
trial POS N
revealed POS N
that POS N
TSM POS N
program POS N
appears POS N
to POS N
be POS N
a POS N
feasible POS N
and POS N
acceptable POS N
intervention POS N
and POS N
may POS N
be POS N
associated POS N
with POS N
short-term POS N
improvements POS N
in POS N
objective POS N
and POS N
subjective POS N
cognitive POS N
function POS N
as POS N
well POS N
as POS N
mental POS N
health POS N
and POS N
spirituality POS N
in POS N
breast POS N
cancer POS N
patients. POS N

Relative POS N
to POS N
the POS N
control POS N
group, POS N
women POS N
in POS N
the POS N
TSM POS N
group POS N
performed POS N
better POS N
on POS N
the POS N
verbal POS N
memory POS N
test POS N
(Rey POS N
Auditory POS N
Verbal POS N
Learning POS N
Test POS N
trial POS N
1) POS N
(p = 0.06) POS N
and POS N
the POS N
short-term POS N
memory POS N
and POS N
processing POS N
speed POS N
task POS N
(Digit POS N
Symbol) POS N
(p = 0.09) POS N
and POS N
reported POS N
improved POS N
cognitive POS N
function POS N
(p = 0.06), POS N
cognitive POS N
abilities POS N
(p = 0.08), POS N
mental POS N
health POS N
(p = 0.04), POS N
and POS N
spirituality POS N
(p = 0.05) POS N
at POS N
the POS N
end POS N
of POS N
treatment POS N
but POS N
not POS N
1 month POS N
later. POS N

Relative POS N
to POS N
the POS N
control POS N
group, POS N
women POS N
in POS N
the POS N
TSM POS N
group POS N
performed POS N
better POS N
on POS N
the POS N
verbal POS N
memory POS N
test POS N
(Rey POS N
Auditory POS N
Verbal POS N
Learning POS N
Test POS N
trial POS N
1) POS N
(p = 0.06) POS N
and POS N
the POS N
short-term POS N
memory POS N
and POS N
processing POS N
speed POS N
task POS N
(Digit POS N
Symbol) POS N
(p = 0.09) POS N
and POS N
reported POS N
improved POS N
cognitive POS N
function POS N
(p = 0.06), POS N
cognitive POS N
abilities POS N
(p = 0.08), POS N
mental POS N
health POS N
(p = 0.04), POS N
and POS N
spirituality POS N
(p = 0.05) POS N
at POS N
the POS N
end POS N
of POS N
treatment POS N
but POS N
not POS N
1 month POS N
later. POS N

This POS N
randomized POS N
controlled POS N
trial POS N
revealed POS N
that POS N
TSM POS N
program POS N
appears POS N
to POS N
be POS N
a POS N
feasible POS N
and POS N
acceptable POS N
intervention POS N
and POS N
may POS N
be POS N
associated POS N
with POS N
short-term POS N
improvements POS N
in POS N
objective POS N
and POS N
subjective POS N
cognitive POS N
function POS N
as POS N
well POS N
as POS N
mental POS N
health POS N
and POS N
spirituality POS N
in POS N
breast POS N
cancer POS N
patients. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Intervention POS N
increased POS N
SF36 POS N
score POS N
by POS N
9.5 POS N
points POS N
(p=0.000006), POS N
4.6 POS N
(p=0.032) POS N
and POS N
6.2 POS N
(p=0.028) POS N
respectively POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Effect POS N
size POS N
(ES) POS N
was POS N
0.63 POS N
[0.37; POS N
0.90], POS N
0.29 POS N
[0.03; POS N
0.55] POS N
and POS N
0.41 POS N
[0.04; POS N
0.78]. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

Anxiety POS N
score POS N
was POS N
shortly POS N
minored POS N
by POS N
intervention POS N
(6-month POS N
ES=-0.24 POS N
[-0.42; POS N
-0.05]) POS N
and POS N
depression POS N
score POS N
more POS N
durably: POS N
ES=-0.45 POS N
[-0.72; POS N
-0.18], POS N
-0.34 POS N
[-061; POS N
-0.08], POS N
and POS N
-0.26 POS N
[-0.63; POS N
0.11] POS N
at POS N
6, POS N
12 POS N
and POS N
24 POS N
months. POS N

Differences, POS N
smaller POS N
at POS N
12 POS N
months POS N
than POS N
at POS N
six, POS N
suggest POS N
that POS N
a POS N
second POS N
but POS N
shorter POS N
intervention POS N
could POS N
help POS N
maintain POS N
the POS N
6-month POS N
benefits. POS N

This POS N
2-week POS N
group POS N
intervention POS N
seemed POS N
to POS N
durably POS N
influence POS N
QoL POS N
of POS N
breast POS N
cancer POS N
patients POS N
treated POS N
by POS N
chemotherapy. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Significant POS N
differences POS N
in POS N
QoL POS N
emerged POS N
in POS N
activity POS N
limitation, POS N
physical POS N
capacity, POS N
and POS N
sexual POS N
functioning, POS N
favouring POS N
IAD. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

No POS N
significant POS N
differences POS N
emerged POS N
in POS N
the POS N
prevalence POS N
of POS N
AEs: POS N
87 POS N
patients POS N
in POS N
the POS N
IAD POS N
arm POS N
(31.8%) POS N
and POS N
95 POS N
in POS N
the POS N
CAD POS N
arm POS N
(33.9%) POS N
had POS N
cardiovascular POS N
(CV) POS N
AEs POS N
(p=0.59), POS N
with POS N
25 POS N
(9.1%) POS N
and POS N
29 POS N
(10.4%) POS N
withdrawn POS N
(p=0.62), POS N
and POS N
21 POS N
(7.7%) POS N
and POS N
24 POS N
(8.6%) POS N
dying POS N
because POS N
of POS N
a POS N
CV POS N
event POS N
(p=0.70), POS N
respectively; POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

bone POS N
fractures POS N
occurred POS N
in POS N
19 POS N
(6.9%) POS N
and POS N
15 POS N
(5.4%) POS N
patients POS N
(p=0.44), POS N
respectively. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Hot POS N
flushes POS N
or POS N
night POS N
sweats POS N
were POS N
the POS N
most POS N
common POS N
ADRs POS N
(47.1% POS N
vs POS N
50.4%; POS N
p=0.44). POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

Erectile POS N
dysfunction POS N
(15.7% POS N
vs POS N
7.9%; POS N
p=0.042) POS N
and POS N
depressed POS N
mood POS N
(2.2 POS N
vs POS N
0%; POS N
p=0.032) POS N
were POS N
more POS N
common POS N
in POS N
the POS N
IAD POS N
arm. POS N

The POS N
prevalence POS N
of POS N
AEs POS N
was POS N
not POS N
significantly POS N
lower POS N
with POS N
IAD. POS N

IAD POS N
showed POS N
benefits POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
PCa POS N
with POS N
respect POS N
to POS N
QoL. POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

CM POS N
five-element POS N
music POS N
group POS N
showed POS N
a POS N
significant POS N
difference POS N
of POS N
HQOLI-R, POS N
KPS POS N
and POS N
symptom POS N
diary POS N
score POS N
with POS N
other POS N
groups POS N
(all POS N
P<0.01). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

There POS N
were POS N
significant POS N
differences POS N
of POS N
HQOLI-R, POS N
symptom POS N
diary POS N
score, POS N
and POS N
KPS POS N
after POS N
treatment POS N
in POS N
CM POS N
five-element POS N
music POS N
group POS N
and POS N
other POS N
groups POS N
in POS N
the POS N
non-senior POS N
subgroup POS N
(P<0.05). POS N

CM POS N
five-element POS N
music POS N
therapy POS N
could POS N
improve POS N
the POS N
quality POS N
of POS N
life POS N
and POS N
KPS POS N
for POS N
senior POS N
and POS N
non POS N
senior POS N
advanced POS N
cancer POS N
patients, POS N
and POS N
it POS N
could POS N
improve POS N
subjective POS N
symptoms POS N
for POS N
non-senior POS N
advanced POS N
cancer POS N
patients. POS N

there POS N
were POS N
significant POS N
differences POS N
in POS N
HQOLI-R POS N
and POS N
KPS POS N
after POS N
treatment POS N
among POS N
the POS N
three POS N
groups POS N
in POS N
the POS N
senior POS N
subgroup POS N
(P<0.05). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Survival POS N
was POS N
inferior POS N
at POS N
1 POS N
year POS N
in POS N
the POS N
oral POS N
etoposide POS N
group POS N
compared POS N
with POS N
intravenous POS N
therapy POS N
(9.8% POS N
for POS N
oral POS N
versus POS N
19.3% POS N
for POS N
intravenous; POS N
difference POS N
= POS N
9.5%; POS N
95% POS N
confidence POS N
interval POS N
of POS N
difference POS N
= POS N
0.3%-18.7%; POS N
P<.05), POS N
and POS N
there POS N
was POS N
a POS N
trend POS N
toward POS N
inferior POS N
overall POS N
survival. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Median POS N
survival POS N
was POS N
4.8 POS N
months POS N
for POS N
oral POS N
treatment POS N
and POS N
5.9 POS N
months POS N
for POS N
intravenous POS N
therapy. POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

Progression-free POS N
survival POS N
was POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
arm POS N
(median POS N
= POS N
3.6 POS N
months POS N
versus POS N
5.6 POS N
months; POS N
P<.001), POS N
as POS N
well POS N
as POS N
overall POS N
response POS N
rate POS N
(32.9% POS N
versus POS N
46.3%; POS N
P<.01). POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

With POS N
the POS N
exception POS N
of POS N
acute POS N
nausea POS N
and POS N
vomiting POS N
associated POS N
with POS N
intravenous POS N
chemotherapy, POS N

all POS N
aspects POS N
of POS N
symptom POS N
control POS N
and POS N
quality POS N
of POS N
life POS N
were POS N
either POS N
the POS N
same POS N
or POS N
worse POS N
in POS N
the POS N
oral POS N
etoposide POS N
group. POS N

These POS N
interim POS N
results POS N
show POS N
that POS N
this POS N
schedule POS N
of POS N
oral POS N
etoposide POS N
is POS N
inferior POS N
to POS N
intravenous POS N
chemotherapy POS N
in POS N
the POS N
treatment POS N
of POS N
advanced POS N
SCLC POS N
and POS N
should POS N
not POS N
be POS N
used POS N
as POS N
first-line POS N
treatment POS N
of POS N
this POS N
disease. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

The POS N
most POS N
commonly POS N
reported POS N
adverse POS N
events POS N
were POS N
nausea, POS N
abdominal POS N
pain, POS N
vomiting POS N
and POS N
fatigue. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
62.5%, POS N
25% POS N
and POS N
60% POS N
had POS N
stable POS N
disease POS N
in POS N
the POS N
120 POS N
mg, POS N
240 POS N
mg POS N
and POS N
placebo POS N
group, POS N
respectively. POS N

Z-360 POS N
is POS N
safe POS N
and POS N
well POS N
tolerated POS N
when POS N
combined POS N
with POS N
gemcitabine. POS N

A POS N
higher POS N
proportion POS N
of POS N
patients POS N
in POS N
Z-360 POS N
groups POS N
reported POS N
improvement POS N
in POS N
pain. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-half POS N
had POS N
hematologic POS N
toxicities POS N
and POS N
toxicity-related POS N
treatment POS N
delays. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Approximately POS N
one-quarter POS N
had POS N
neurotoxicities POS N
and/or POS N
ototoxicites, POS N
moist POS N
desquamation, POS N
pneumonia, POS N
nausea POS N
and POS N
vomiting POS N
requiring POS N
hospitalization POS N
or POS N
intravenous POS N
fluids, POS N
dehydration POS N
or POS N
malnutrition POS N
requiring POS N
hospitalization, POS N
and POS N
mild POS N
or POS N
moderate POS N
fever. POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

Although POS N
patients POS N
receiving POS N
the POS N
current POS N
intensity-modulated POS N
radiation POS N
therapy POS N
(IMRT) POS N
protocol POS N
using POS N
the POS N
Pinnacle(3) POS N
planning POS N
system POS N
had POS N
more POS N
toxicity-related POS N
treatment POS N
delays, POS N

Patients POS N
receiving POS N
CRT POS N
experience POS N
a POS N
substantial POS N
number POS N
of POS N
treatment-related POS N
adverse POS N
events, POS N
primarily POS N
affecting POS N
oropharyngeal POS N
and POS N
laryngeal POS N
function, POS N
with POS N
improvement POS N
noted POS N
for POS N
the POS N
current POS N
IMRT POS N
protocol. POS N

they POS N
had POS N
fewer POS N
toxicities POS N
and POS N
better POS N
functional POS N
and POS N
health-related POS N
quality POS N
of POS N
life POS N
outcomes POS N
compared POS N
with POS N
those POS N
receiving POS N
conventional POS N
lateral POS N
opposing-field POS N
radiation POS N
or POS N
the POS N
initial POS N
IMRT POS N
protocol POS N
using POS N
the POS N
Best POS N
nomos POS N
PEACOCK POS N
planning POS N
system. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Fecal POS N
incontinence POS N
seems POS N
to POS N
be POS N
a POS N
problem. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
outcome POS N
of POS N
these POS N
patients POS N
remains POS N
unsatisfactory. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Prognostic POS N
factors POS N
for POS N
a POS N
favorable POS N
outcome POS N
are POS N
tumor POS N
size POS N
of POS N
smaller POS N
than POS N
5 POS N
cm, POS N
negative POS N
locoregional POS N
lymph POS N
nodes, POS N
age POS N
less POS N
than POS N
10 POS N
years, POS N
low POS N
IRS POS N
group, POS N
and POS N
embryonal POS N
histology. POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

The POS N
median POS N
Wexner POS N
fecal POS N
incontinence POS N
score POS N
was POS N
9 POS N
(possible POS N
range: POS N
0-20), POS N
and POS N
the POS N
median POS N
QOL POS N
score POS N
was POS N
90.5 POS N
(applicable POS N
range: POS N
0-144). POS N

Patients POS N
with POS N
embryonal POS N
histology POS N
had POS N
a POS N
significantly POS N
better POS N
5-year POS N
EFS POS N
(87.5%) POS N
than POS N
patients POS N
with POS N
alveolar POS N
histology POS N
(39.1%; POS N
P POS N
= POS N
0.013). POS N

Some POS N
patients POS N
reported POS N
symptoms POS N
of POS N
fecal POS N
incontinence. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Of POS N
the POS N
patients POS N
in POS N
the POS N
one-stage POS N
group, POS N
70 POS N
percent POS N
had POS N
revision POS N
surgery, POS N
mostly POS N
because POS N
of POS N
upper POS N
pole POS N
fullness POS N
and POS N
poor POS N
ptosis. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
in POS N
the POS N
two POS N
groups. POS N

The POS N
crescent POS N
two-stage POS N
method POS N
gave POS N
the POS N
most POS N
acceptable POS N
results POS N
both POS N
objectively POS N
and POS N
subjectively. POS N

The POS N
permanent POS N
expander POS N
method POS N
failed POS N
significantly POS N
as POS N
a POS N
one-stage POS N
procedure. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

At POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
13.5 POS N
months POS N
(range POS N
1-28+) POS N
at POS N
June POS N
2001, POS N
among POS N
26 POS N
patients POS N
enrolled POS N
12 POS N
(46.1%) POS N
were POS N
still POS N
alive POS N
and POS N
9 POS N
(75%) POS N
of POS N
them POS N
were POS N
progression-free. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
was POS N
9 POS N
months POS N
(range POS N
0-25+), POS N
the POS N
median POS N
progression-free POS N
survival POS N
was POS N
10.5 POS N
months POS N
(range POS N
0-28+), POS N
the POS N
median POS N
overall POS N
survival POS N
time POS N
was POS N
9 POS N
months POS N
(range POS N
1-22). POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

The POS N
toxicity POS N
was POS N
significant POS N
and POS N
consisted POS N
mainly POS N
of POS N
mucositis POS N
and, POS N
to POS N
a POS N
lesser POS N
extent, POS N
neutropenia/thrombocytopenia. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

the POS N
low POS N
serum POS N
levels POS N
of POS N
leptin POS N
and POS N
the POS N
high POS N
serum POS N
levels POS N
of POS N
proinflammatory POS N
cytokines POS N
in POS N
advanced POS N
stage POS N
cancer POS N
patients POS N
were POS N
confirmed. POS N

this POS N
regimen POS N
could POS N
not POS N
be POS N
recommended POS N
for POS N
a POS N
phase POS N
III POS N
randomized POS N
study. POS N

this POS N
sequential POS N
induction POS N
chemotherapy POS N
and POS N
chemoradiotherapy POS N
program POS N
has POS N
been POS N
found POS N
moderately POS N
active POS N
and POS N
significantly POS N
toxic; POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
partial POS N
and POS N
complete POS N
response POS N
rate POS N
(PR POS N
+ POS N
CR) POS N
was POS N
significantly POS N
greater POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
when POS N
measured POS N
by POS N
tumor POS N
areas POS N
(44%) POS N
vs. POS N
17.6%, POS N
P POS N
= POS N
0.01) POS N
tumor POS N
volumes POS N
(50% POS N
vs. POS N
24%, POS N
P POS N
= POS N
0.03) POS N
and POS N
CEA POS N
(72% POS N
vs. POS N
47%, POS N
P POS N
= POS N
0.004). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
median POS N
time POS N
to POS N
disease POS N
progression POS N
in POS N
the POS N
liver POS N
was POS N
significantly POS N
longer POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone POS N
when POS N
measured POS N
by POS N
either POS N
tumor POS N
areas POS N
(9.7 POS N
vs. POS N
15.9 POS N
months, POS N
P POS N
= POS N
0.001), POS N
tumor POS N
volumes POS N
(7.6 POS N
vs. POS N
12.0 POS N
months, POS N
P POS N
= POS N
0.04) POS N
or POS N
CEA POS N
(5.7 POS N
vs. POS N
6.7 POS N
months, POS N
P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

The POS N
one, POS N
two, POS N
three POS N
and POS N
five-year POS N
survival POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
was POS N
72%, POS N
39%, POS N
17% POS N
and POS N
3.5%, POS N
compared POS N
to POS N
68%, POS N
29%, POS N
6.5% POS N
and POS N
0% POS N
for POS N
HAC POS N
alone. POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

Cox POS N
regression POS N
analysis POS N
suggests POS N
an POS N
improvement POS N
in POS N
survival POS N
for POS N
patients POS N
treated POS N
with POS N
SIR-Spheres POS N
who POS N
survive POS N
more POS N
than POS N
15 POS N
months POS N
(P POS N
= POS N
0.06). POS N

The POS N
combination POS N
of POS N
a POS N
single POS N
injection POS N
of POS N
SIR-Spheres POS N
plus POS N
HAC POS N
is POS N
substantially POS N
more POS N
effective POS N
in POS N
increasing POS N
tumor POS N
responses POS N
and POS N
progression POS N
free POS N
survival POS N
than POS N
the POS N
same POS N
regimen POS N
of POS N
HAC POS N
alone. POS N

There POS N
was POS N
no POS N
increase POS N
in POS N
grade POS N
3-4 POS N
treatment POS N
related POS N
toxicity POS N
and POS N
no POS N
loss POS N
of POS N
quality POS N
of POS N
life POS N
for POS N
patients POS N
receiving POS N
SIR-Spheres POS N
in POS N
comparison POS N
to POS N
patients POS N
receiving POS N
HAC POS N
alone. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Phase POS N
II POS N
and POS N
III POS N
studies POS N
have POS N
shown POS N
that POS N
the POS N
addition POS N
of POS N
interleukin-2 POS N
(IL-2) POS N
and POS N
interferon POS N
alpha-2b POS N
(IFN POS N
alpha-2b) POS N
in POS N
multiagent POS N
chemotherapy POS N
(CT) POS N
for POS N
advanced POS N
melanoma POS N
increases POS N
overall POS N
response POS N
(OR), POS N
albeit POS N
without POS N
clear POS N
evidence POS N
of POS N
an POS N
improvement POS N
in POS N
overall POS N
survival POS N
(OS). POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment POS N
with POS N
high-dose POS N
IL-2 POS N
can POS N
cause POS N
severe POS N
toxicity POS N
and POS N
is POS N
normally POS N
administered POS N
in POS N
an POS N
inpatient POS N
setting. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
18 POS N
(CT) POS N
and POS N
16 POS N
(bioCT) POS N
months, POS N
median POS N
OS POS N
was POS N
9.5 POS N
versus POS N
11.0 POS N
months POS N
(P POS N
=.51), POS N
respectively. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
89 POS N
CT-arm POS N
patients, POS N
18 POS N
ORs POS N
(20.2%) POS N
(three POS N
complete POS N
responders POS N
[CRs] POS N
and POS N
15 POS N
partial POS N
responders POS N
[PRs]) POS N
were POS N
observed POS N
according POS N
to POS N
World POS N
Health POS N
Organization POS N
criteria. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

In POS N
the POS N
87 POS N
bioCT-arm POS N
patients, POS N
22 POS N
ORs POS N
(25.3%) POS N
(three POS N
CRs POS N
and POS N
19 POS N
PRs) POS N
(P POS N
=.70) POS N
were POS N
recorded. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

Treatment-related POS N
toxicity POS N
was POS N
fairly POS N
similar POS N
in POS N
both POS N
arms. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

The POS N
addition POS N
of POS N
low-dose POS N
immunotherapy POS N
did POS N
not POS N
produce POS N
a POS N
statistically POS N
significant POS N
advantage POS N
in POS N
OS, POS N
time POS N
to POS N
progression, POS N
or POS N
OR. POS N

our POS N
treatment POS N
schedule POS N
was POS N
carried POS N
out POS N
on POS N
outpatients POS N
and POS N
had POS N
an POS N
acceptable POS N
level POS N
of POS N
toxicity. POS N

However, POS N
the POS N
11-month POS N
median POS N
OS POS N
in POS N
the POS N
bioCT POS N
arm POS N
does POS N
not POS N
differ POS N
greatly POS N
from POS N
the POS N
best POS N
results POS N
with POS N
high-dose POS N
IL-2-containing POS N
regimens POS N
reported POS N
in POS N
the POS N
literature. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Median POS N
PFS POS N
was POS N
2.3 POS N
months POS N
for POS N
each POS N
arm POS N
(HR, POS N
1.004; POS N
95% POS N
CI, POS N
0.841 POS N
to POS N
1.199). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

ORR, POS N
stable POS N
disease, POS N
median POS N
OS, POS N
were POS N
4.4% POS N
versus POS N
5.5%, POS N
36.0% POS N
versus POS N
39.6%, POS N
6.7 POS N
versus POS N
7.2 POS N
months POS N
(HR, POS N
0.973; POS N
95% POS N
CI, POS N
0.805 POS N
to POS N
1.176), POS N
respectively. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
significant POS N
difference POS N
in POS N
patient POS N
benefit POS N
and POS N
QOL POS N
(Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy-Lung). POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

No POS N
unexpected POS N
adverse POS N
events POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Grade POS N
higher POS N
than POS N
0 POS N
(vinflunine POS N
v POS N
docetaxel) POS N
anemia POS N
(82.1% POS N
v POS N
79.8%), POS N
neutropenia POS N
(49.3 POS N
v POS N
39.02%), POS N
thrombocytopenia POS N
(30.6% POS N
v POS N
14.3%), POS N
febrile POS N
neutropenia POS N
(3.3% POS N
v POS N
4.7%), POS N
constipation POS N
(39.2% POS N
v POS N
11.7%), POS N
fatigue POS N
(36.6% POS N
v POS N
33.9%), POS N
injection POS N
site POS N
reaction POS N
(31.9% POS N
v POS N
0.7%), POS N
nausea POS N
(26.7% POS N
v POS N
23.7%), POS N
vomiting POS N
(23.8% POS N
v POS N
14.2%), POS N
alopecia POS N
(19.8% POS N
v POS N
35.4%), POS N
stomatis POS N
(19.4% POS N
v POS N
12.4%), POS N
abdominal POS N
pain POS N
(20.1% POS N
v POS N
3.6%), POS N
myalgia POS N
(14.7% POS N
v POS N
6.6%), POS N
peripheral POS N
neuropathy POS N
(10.7% POS N
v POS N
15.0%), POS N
arthralgia POS N
(7.0% POS N
v POS N
7.7%), POS N
diarrhea POS N
(6.2% POS N
v POS N
12.4%), POS N
edema POS N
(1.5% POS N
v POS N
5.4%), POS N
and POS N
nail POS N
disorders POS N
(1.1% POS N
v POS N
5;1%) POS N
were POS N
observed. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

This POS N
noninferiority POS N
phase POS N
III POS N
study POS N
showed POS N
similar POS N
efficacy POS N
end POS N
points POS N
for POS N
vinflunine POS N
and POS N
docetaxel. POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

Despite POS N
higher POS N
rates POS N
of POS N
some POS N
adverse POS N
effects POS N
(anemia, POS N
abdominal POS N
pain, POS N
constipation, POS N
fatigue) POS N

VFL POS N
may POS N
be POS N
another POS N
option POS N
in POS N
the POS N
second-line POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

the POS N
overall POS N
toxicity POS N
profile POS N
of POS N
vinflunine POS N
was POS N
manageable. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

overall POS N
survival POS N
was POS N
similar. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

overall POS N
survival POS N
was POS N
similar. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

overall POS N
survival POS N
was POS N
similar. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

overall POS N
survival POS N
was POS N
similar. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

overall POS N
survival POS N
was POS N
similar. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

overall POS N
survival POS N
was POS N
similar. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

overall POS N
survival POS N
was POS N
similar. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

overall POS N
survival POS N
was POS N
similar. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

overall POS N
survival POS N
was POS N
similar. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Suramin POS N
is POS N
a POS N
novel POS N
agent POS N
that POS N
has POS N
demonstrated POS N
preliminary POS N
evidence POS N
of POS N
antitumor POS N
activity POS N
in POS N
hormone-refractory POS N
prostate POS N
cancer POS N
(HRPC). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Overall POS N
mean POS N
reductions POS N
in POS N
combined POS N
pain POS N
and POS N
opioid POS N
analgesic POS N
intake POS N
were POS N
greater POS N
for POS N
suramin POS N
plus POS N
HC POS N
(rank POS N
sum POS N
P POS N
=.0001). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Pain POS N
response POS N
was POS N
achieved POS N
in POS N
a POS N
higher POS N
proportion POS N
of POS N
patients POS N
receiving POS N
suramin POS N
than POS N
placebo POS N
(43% POS N
v POS N
28%; POS N
P POS N
=.001), POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

duration POS N
of POS N
response POS N
was POS N
longer POS N
for POS N
suramin POS N
responders POS N
(median, POS N
240 POS N
v POS N
69 POS N
days; POS N
P POS N
=.0027). POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Time POS N
to POS N
disease POS N
progression POS N
was POS N
longer POS N
(relative POS N
risk POS N
= POS N
1.5; POS N
95% POS N
confidence POS N
interval, POS N
1.2 POS N
to POS N
1.9) POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

the POS N
proportion POS N
of POS N
patients POS N
with POS N
a POS N
greater POS N
than POS N
50% POS N
decline POS N
in POS N
PSA POS N
was POS N
higher POS N
(33% POS N
v POS N
16%; POS N
P POS N
=.01) POS N
in POS N
patients POS N
who POS N
received POS N
suramin. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Neither POS N
quality POS N
of POS N
life POS N
nor POS N
performance POS N
status POS N
was POS N
decreased POS N
by POS N
suramin POS N
treatment, POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

overall POS N
survival POS N
was POS N
similar. POS N

Outpatient POS N
treatment POS N
with POS N
suramin POS N
plus POS N
HC POS N
is POS N
well POS N
tolerated POS N
and POS N
provides POS N
moderate POS N
palliative POS N
benefit POS N
and POS N
delay POS N
in POS N
disease POS N
progression POS N
for POS N
patients POS N
with POS N
symptomatic POS N
HRPC. POS N

Most POS N
adverse POS N
events POS N
were POS N
of POS N
mild POS N
or POS N
moderate POS N
intensity POS N
and POS N
were POS N
easily POS N
managed POS N
medically. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Patients POS N
receiving POS N
MA POS N
reported POS N
substantially POS N
better POS N
appetite POS N
(P POS N
= POS N
0.001), POS N
mood POS N
(P POS N
= POS N
0.001) POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
(P POS N
< POS N
0.001), POS N
and POS N
possibly POS N
less POS N
nausea POS N
and POS N
vomiting POS N
(P POS N
= POS N
0.08) POS N
than POS N
patients POS N
receiving POS N
placebo, POS N
based POS N
on POS N
a POS N
test POS N
for POS N
trend. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

A POS N
larger POS N
benefit POS N
was POS N
seen POS N
with POS N
the POS N
higher POS N
dose POS N
which POS N
(unlike POS N
the POS N
lower POS N
dose) POS N
was POS N
significantly POS N
better POS N
in POS N
pairwise POS N
comparisons POS N
with POS N
placebo POS N
for POS N
appetite, POS N
mood POS N
and POS N
overall POS N
QoL POS N
(each POS N
P POS N
< POS N
or POS N
= POS N
0.001). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Despite POS N
some POS N
missing POS N
data POS N
on POS N
QoL POS N
scores, POS N
QoL POS N
ranking POS N
was POS N
available POS N
on POS N
227 POS N
(95%) POS N
of POS N
patients POS N
with POS N
significantly POS N
higher POS N
QoL POS N
ranking POS N
associated POS N
with POS N
MA POS N
(P POS N
= POS N
0.002). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Improvements POS N
in POS N
QoL POS N
occurred POS N
early POS N
within POS N
four POS N
weeks POS N
and POS N
were POS N
sustained. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

No POS N
statistically POS N
significant POS N
differences POS N
were POS N
observed POS N
in POS N
NS POS N
measurements, POS N
including POS N
weight POS N
(P POS N
= POS N
0.29). POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Side POS N
effects POS N
of POS N
therapy POS N
were POS N
minor POS N
and POS N
did POS N
not POS N
differ POS N
significantly POS N
across POS N
treatments. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

Megestrol POS N
acetate POS N
given POS N
at POS N
480 POS N
mg/day POS N
is POS N
useful POS N
palliation POS N
in POS N
patients POS N
with POS N
endocrine-insensitive POS N
advanced POS N
cancer. POS N

although POS N
not POS N
through POS N
a POS N
direct POS N
effect POS N
on POS N
nutritional POS N
status. POS N

It POS N
improves POS N
appetite, POS N
mood POS N
and POS N
overall POS N
quality POS N
of POS N
life POS N
in POS N
these POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients, POS N
even POS N
if POS N
fit, POS N
are POS N
often POS N
considered POS N
incapable POS N
of POS N
tolerating POS N
platinum-based POS N
systemic POS N
therapy. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Older POS N
patients POS N
had POS N
a POS N
higher POS N
incidence POS N
of POS N
cardiovascular POS N
(P POS N
=.009) POS N
and POS N
respiratory POS N
(P POS N
=.04) POS N
comorbidities POS N
and POS N
nonanalgesic POS N
medication POS N
use POS N
(P POS N
=.02). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Leukopenia POS N
(P<.001) POS N
and POS N
neuropsychiatric POS N
toxicity POS N
(P POS N
=.002) POS N
were POS N
more POS N
common POS N
in POS N
elderly POS N
men POS N
than POS N
in POS N
younger POS N
men. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Elderly POS N
women POS N
lost POS N
more POS N
weight POS N
than POS N
younger POS N
women POS N
(P POS N
=.006). POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

The POS N
proportions POS N
with POS N
clinical POS N
partial POS N
or POS N
complete POS N
response POS N
(21.5% POS N
versus POS N
23.3%; POS N
Fisher's POS N
exact POS N
test, POS N
P POS N
=.66), POS N
median POS N
time POS N
to POS N
progression POS N
(4.37 POS N
versus POS N
4.30 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.29), POS N
and POS N
survival POS N
distribution POS N
(log-rank POS N
test, POS N
P POS N
=.29; POS N
median POS N
survival, POS N
9.05 POS N
versus POS N
8.53 POS N
months; POS N
1-year POS N
survival, POS N
38% POS N
versus POS N
29%; POS N
and POS N
2-year POS N
survival, POS N
14% POS N
versus POS N
12%) POS N
were POS N
similar POS N
in POS N
patients POS N
younger POS N
than POS N
70 POS N
years POS N
and POS N
70 POS N
years POS N
old POS N
or POS N
older. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Baseline POS N
quality-of-life POS N
and POS N
treatment-outcome POS N
indices POS N
were POS N
similar. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Equivalent POS N
declines POS N
over POS N
time POS N
in POS N
functional POS N
well-being POS N
occurred POS N
in POS N
both POS N
groups. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Advanced POS N
age POS N
alone POS N
should POS N
not POS N
preclude POS N
appropriate POS N
NSCLC POS N
treatment. POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

Response POS N
rate, POS N
toxicity, POS N
and POS N
survival POS N
in POS N
fit, POS N
elderly POS N
NSCLC POS N
patients POS N
receiving POS N
platinum-based POS N
treatment POS N
appear POS N
to POS N
be POS N
similar POS N
to POS N
those POS N
in POS N
younger POS N
patients, POS N

Other POS N
toxic POS N
effects POS N
were POS N
similar POS N
in POS N
older POS N
and POS N
younger POS N
patients. POS N

although POS N
patients POS N
70 POS N
years POS N
old POS N
or POS N
older POS N
have POS N
more POS N
comorbidities POS N
and POS N
can POS N
expect POS N
more POS N
leukopenia POS N
and POS N
neuropsychiatric POS N
toxicity. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Treatment POS N
with POS N
EVE POS N
+ POS N
EXE POS N
significantly POS N
improved POS N
median POS N
PFS POS N
versus POS N
PBO POS N
+ POS N
EXE POS N
among POS N
Asian POS N
patients POS N
by POS N
38 POS N
% POS N
(HR POS N
= POS N
0.62; POS N
95 POS N
% POS N
CI, POS N
0.41-0.94). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
was POS N
also POS N
improved POS N
among POS N
non-Asian POS N
patients POS N
by POS N
59 POS N
% POS N
(HR POS N
= POS N
0.41; POS N
95 POS N
% POS N
CI, POS N
0.33-0.50). POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Median POS N
PFS POS N
duration POS N
among POS N
EVE-treated POS N
Asian POS N
patients POS N
was POS N
8.48 POS N
versus POS N
4.14 POS N
months POS N
for POS N
PBO POS N
+ POS N
EXE, POS N
and POS N
7.33 POS N
versus POS N
2.83 POS N
months, POS N
respectively, POS N
in POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

The POS N
most POS N
common POS N
grade POS N
3/4 POS N
adverse POS N
events POS N
(stomatitis, POS N
anemia, POS N
elevated POS N
liver POS N
enzymes, POS N
hyperglycemia, POS N
and POS N
dyspnea) POS N
occurred POS N
at POS N
similar POS N
frequencies POS N
in POS N
Asian POS N
and POS N
non-Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Grade POS N
1/2 POS N
interstitial POS N
lung POS N
disease POS N
occurred POS N
more POS N
frequently POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Quality POS N
of POS N
life POS N
was POS N
similar POS N
between POS N
treatment POS N
arms POS N
in POS N
Asian POS N
patients. POS N

This POS N
combination POS N
represents POS N
an POS N
improvement POS N
in POS N
the POS N
management POS N
of POS N
postmenopausal POS N
women POS N
with POS N
HR(+)/HER2(-) POS N
advanced POS N
breast POS N
cancer POS N
progressing POS N
on POS N
nonsteroidal POS N
aromatase POS N
inhibitors, POS N
regardless POS N
of POS N
ethnicity. POS N

Adding POS N
EVE POS N
to POS N
EXE POS N
provided POS N
substantial POS N
clinical POS N
benefit POS N
in POS N
both POS N
Asian POS N
and POS N
non-Asian POS N
patients POS N
with POS N
similar POS N
safety POS N
profiles. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
overall POS N
or POS N
cancer-specific POS N
survival POS N
between POS N
the POS N
2 POS N
arms. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
the POS N
2 POS N
arms POS N
at POS N
0 POS N
and POS N
12 POS N
months. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
total POS N
mean POS N
costs POS N
at POS N
24 POS N
months POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
intermittent POS N
arm POS N
($3135 POS N
vs. POS N
$8253 POS N
Canadian POS N
dollars, POS N
P=0.0167) POS N
compared POS N
with POS N
the POS N
continuous. POS N

We POS N
have POS N
observed POS N
that POS N
intermittent POS N
ADT POS N
in POS N
patients POS N
with POS N
CRPCa, POS N
using POS N
a POS N
testosterone POS N
of POS N
>1.75 POS N
ngmol/L POS N
as POS N
a POS N
trigger POS N
to POS N
reinitiate POS N
LHRHa, POS N
results POS N
in POS N
a POS N
substantial POS N
cost POS N
savings POS N
with POS N
no POS N
negative POS N
impact POS N
on POS N
oncologic POS N
and POS N
QOL POS N
outcomes. POS N

The POS N
main POS N
limitation POS N
of POS N
this POS N
study POS N
is POS N
the POS N
small POS N
sample POS N
size. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Pain POS N
reduction POS N
was POS N
significant POS N
from POS N
day POS N
4 POS N
till POS N
end POS N
of POS N
treatment POS N
with POS N
SAMITAL® POS N
and POS N
from POS N
days POS N
7 POS N
to POS N
21 POS N
in POS N
placebo POS N
patients. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
significant POS N
improvement POS N
was POS N
observed POS N
in POS N
the POS N
placebo POS N
group POS N
(n POS N
= POS N
10). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

Mean POS N
scores POS N
for POS N
the POS N
severity POS N
of POS N
OM POS N
were POS N
significantly POS N
(p POS N
< POS N
0.05 POS N
versus POS N
baseline) POS N
reduced POS N
from POS N
day POS N
31 POS N
until POS N
the POS N
end POS N
of POS N
treatment POS N
in POS N
patients POS N
treated POS N
with POS N
SAMITAL® POS N
(n POS N
= POS N
20). POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
also POS N
significantly POS N
improved POS N
quality POS N
of POS N
life, POS N
as POS N
shown POS N
by POS N
improvements POS N
in POS N
scores POS N
for POS N
relevant POS N
daily POS N
activities POS N
including POS N
eating, POS N
drinking POS N
and POS N
sleeping. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

No POS N
severe POS N
adverse POS N
events POS N
were POS N
observed POS N
with POS N
SAMITAL®, POS N
and POS N
systemic POS N
absorption POS N
of POS N
relevant POS N
active POS N
ingredients POS N
was POS N
undetectable. POS N

Pain POS N
relief POS N
lasted POS N
through POS N
the POS N
treatment POS N
period, POS N
and POS N
improvements POS N
in POS N
quality POS N
of POS N
life POS N
were POS N
reflected POS N
by POS N
the POS N
significant POS N
benefits POS N
of POS N
SAMITAL® POS N
on POS N
activities POS N
like POS N
drinking, POS N
eating POS N
and POS N
speaking. POS N

SAMITAL® POS N
significantly POS N
decreased POS N
the POS N
severity POS N
of POS N
chemo/radiotherapy-induced POS N
OM POS N
in POS N
patients POS N
with POS N
head POS N
and POS N
neck POS N
cancer, POS N
with POS N
no POS N
treatment-related POS N
adverse POS N
events. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
0, POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
mean POS N
urine POS N
loss POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
bladder POS N
neck POS N
preservation POS N
group POS N
was POS N
713.3 POS N
vs POS N
237.0, POS N
49.6 POS N
vs POS N
15.6, POS N
44.4 POS N
vs POS N
5.5 POS N
and POS N
25.4 POS N
vs POS N
3.1 POS N
gm, POS N
respectively POS N
(each POS N
p POS N
<0.001). POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

At POS N
3, POS N
6 POS N
and POS N
12 POS N
months POS N
in POS N
the POS N
control POS N
vs POS N
the POS N
preservation POS N
group POS N
the POS N
social POS N
continence POS N
rate POS N
was POS N
55.3% POS N
vs POS N
84.2% POS N
(p POS N
<0.001), POS N
74.8% POS N
vs POS N
89.5% POS N
(p POS N
= POS N
0.05) POS N
and POS N
81.4% POS N
vs POS N
94.7% POS N
(p POS N
= POS N
0.027), POS N
and POS N
the POS N
quality POS N
of POS N
life POS N
score POS N
was POS N
80.4 POS N
vs POS N
90.3 POS N
(p POS N
<0.001), POS N
85.4 POS N
vs POS N
91.7 POS N
(p POS N
= POS N
0.016) POS N
and POS N
86.0 POS N
vs POS N
93.8 POS N
(p POS N
= POS N
0.001), POS N
respectively. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

We POS N
noted POS N
significantly POS N
less POS N
urine POS N
loss, POS N
higher POS N
objective POS N
and POS N
social POS N
continence POS N
rates, POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
scores POS N
after POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
at POS N
all POS N
followup POS N
points. POS N

In POS N
what POS N
is POS N
to POS N
our POS N
knowledge POS N
the POS N
first POS N
prospective, POS N
randomized, POS N
controlled, POS N
single POS N
blind POS N
trial POS N
complete POS N
bladder POS N
neck POS N
preservation POS N
during POS N
radical POS N
prostatectomy POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
urinary POS N
continence POS N
rate POS N
and POS N
increased POS N
patient POS N
satisfaction POS N
without POS N
compromising POS N
resection POS N
margins. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
surgical POS N
margin POS N
status POS N
between POS N
the POS N
control POS N
and POS N
bladder POS N
neck POS N
preservation POS N
groups POS N
(12.5% POS N
vs POS N
14.7%, POS N
p POS N
= POS N
0.65). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

The POS N
2-weekly POS N
administration POS N
was POS N
associated POS N
with POS N
significantly POS N
longer POS N
TTTF POS N
than POS N
was POS N
3-weekly POS N
administration POS N
(5·6 POS N
months, POS N
95% POS N
CI POS N
5·0-6·2 POS N
vs POS N
4·9 POS N
months, POS N
4·5-5·4; POS N
hazard POS N
ratio POS N
1·3, POS N
95% POS N
CI POS N
1·1-1·6, POS N
p=0·014). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Grade POS N
3-4 POS N
adverse POS N
events POS N
occurred POS N
more POS N
frequently POS N
in POS N
the POS N
3-weekly POS N
than POS N
in POS N
the POS N
2-weekly POS N
administration POS N
group, POS N
including POS N
neutropenia POS N
(93 POS N
[53%] POS N
vs POS N
61 POS N
[36%]), POS N
leucopenia POS N
(51 POS N
[29%] POS N
vs POS N
22 POS N
[13%]), POS N
and POS N
febrile POS N
neutropenia POS N
(25 POS N
[14%] POS N
vs POS N
six POS N
[4%]). POS N

Administration POS N
of POS N
docetaxel POS N
every POS N
2 POS N
weeks POS N
seems POS N
to POS N
be POS N
well POS N
tolerated POS N
in POS N
patients POS N
with POS N
castration-resistant POS N
advanced POS N
prostate POS N
cancer POS N
and POS N
could POS N
be POS N
a POS N
useful POS N
option POS N
when POS N
3-weekly POS N
single-dose POS N
administration POS N
is POS N
unlikely POS N
to POS N
be POS N
tolerated. POS N

Neutropenic POS N
infections POS N
were POS N
reported POS N
more POS N
frequently POS N
in POS N
patients POS N
who POS N
received POS N
docetaxel POS N
every POS N
3 POS N
weeks POS N
(43 POS N
[24%] POS N
vs POS N
11 POS N
[6%], POS N
p=0·002). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
objective POS N
response POS N
rate POS N
was POS N
26% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
18.2% POS N
to POS N
34.4%), POS N
with POS N
seven POS N
complete POS N
and POS N
23 POS N
partial POS N
responses. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Response POS N
rates POS N
in POS N
111 POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
by POS N
immunohistochemistry POS N
(IHC) POS N
were POS N
35% POS N
(95% POS N
CI, POS N
24.4% POS N
to POS N
44.7%) POS N
and POS N
none POS N
(95% POS N
CI, POS N
0% POS N
to POS N
15.5%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
clinical POS N
benefit POS N
rates POS N
in POS N
assessable POS N
patients POS N
with POS N
3+ POS N
and POS N
2+ POS N
HER2 POS N
overexpression POS N
were POS N
48% POS N
and POS N
7%, POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
response POS N
rates POS N
in POS N
108 POS N
assessable POS N
patients POS N
with POS N
and POS N
without POS N
HER2 POS N
gene POS N
amplification POS N
by POS N
fluorescence POS N
in POS N
situ POS N
hybridization POS N
(FISH) POS N
analysis POS N
were POS N
34% POS N
(95% POS N
CI, POS N
23.9% POS N
to POS N
45.7%) POS N
and POS N
7% POS N
(95% POS N
CI, POS N
0.8% POS N
to POS N
22.8%), POS N
respectively. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Seventeen POS N
(57%) POS N
of POS N
30 POS N
patients POS N
with POS N
an POS N
objective POS N
response POS N
and POS N
22 POS N
(51%) POS N
of POS N
43 POS N
patients POS N
with POS N
clinical POS N
benefit POS N
had POS N
not POS N
experienced POS N
disease POS N
progression POS N
at POS N
follow-up POS N
at POS N
12 POS N
months POS N
or POS N
later. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

The POS N
most POS N
common POS N
treatment-related POS N
adverse POS N
events POS N
were POS N
chills POS N
(25% POS N
of POS N
patients), POS N
asthenia POS N
(23%), POS N
fever POS N
(22%), POS N
pain POS N
(18%), POS N
and POS N
nausea POS N
(14%). POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

Cardiac POS N
dysfunction POS N
occurred POS N
in POS N
two POS N
patients POS N
(2%); POS N
both POS N
had POS N
histories POS N
of POS N
cardiac POS N
disease POS N
and POS N
did POS N
not POS N
require POS N
additional POS N
intervention POS N
after POS N
discontinuation POS N
of POS N
trastuzumab. POS N

Single-agent POS N
trastuzumab POS N
is POS N
active POS N
and POS N
well POS N
tolerated POS N
as POS N
first-line POS N
treatment POS N
of POS N
women POS N
with POS N
metastatic POS N
breast POS N
cancer POS N
with POS N
HER2 POS N
3+ POS N
overexpression POS N
by POS N
IHC POS N
or POS N
gene POS N
amplification POS N
by POS N
FISH. POS N

There POS N
was POS N
no POS N
clear POS N
evidence POS N
of POS N
a POS N
dose-response POS N
relationship POS N
for POS N
response, POS N
survival, POS N
or POS N
adverse POS N
events. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Treatment POS N
was POS N
well POS N
tolerated POS N
in POS N
both POS N
groups, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

although POS N
local POS N
and POS N
systemic POS N
side POS N
effects POS N
were POS N
more POS N
frequently POS N
reported POS N
in POS N
the POS N
bacillus POS N
Calmette-Guérin POS N
arm. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

Multivariate POS N
analyses POS N
showed POS N
no POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
groups POS N
in POS N
all POS N
quality POS N
of POS N
life POS N
dimensions. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
changes POS N
over POS N
time POS N
in POS N
quality POS N
of POS N
life POS N
domains POS N
were POS N
detected POS N
for POS N
patients POS N
on POS N
bacillus POS N
Calmette-Guérin POS N
and POS N
gemcitabine POS N
except POS N
for POS N
physical POS N
functioning, POS N
which POS N
decreased POS N
significantly POS N
in POS N
both POS N
groups POS N
(p POS N
= POS N
0.002). POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

No POS N
significant POS N
differences POS N
were POS N
detected POS N
in POS N
terms POS N
of POS N
recurrence POS N
and POS N
progression POS N
between POS N
the POS N
2 POS N
groups POS N
at POS N
1-year POS N
followup. POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

a POS N
higher POS N
rate POS N
of POS N
side POS N
effects, POS N
albeit POS N
mild POS N
to POS N
moderate, POS N
was POS N
detected POS N
with POS N
1/3 POS N
dose POS N
bacillus POS N
Calmette-Guérin POS N
compared POS N
to POS N
gemcitabine, POS N

Bacillus POS N
Calmette-Guérin POS N
and POS N
intravesical POS N
chemotherapy POS N
represent POS N
viable POS N
adjuvant POS N
options POS N
for POS N
intermediate POS N
risk POS N
nonmuscle POS N
invasive POS N
bladder POS N
cancer. POS N

our POS N
study POS N
failed POS N
to POS N
show POS N
significant POS N
differences POS N
between POS N
the POS N
2 POS N
drugs POS N
in POS N
terms POS N
of POS N
quality POS N
of POS N
life. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

For POS N
patients POS N
with POS N
advanced POS N
gastric POS N
or POS N
gastroesophageal POS N
cancer POS N
(AGGEC) POS N
providing POS N
clinical POS N
benefit POS N
with POS N
improved POS N
palliation POS N
is POS N
highly POS N
desirable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

DCF POS N
significantly POS N
prolonged POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
KPS POS N
compared POS N
with POS N
CF POS N
(median, POS N
6.1 POS N
v POS N
4.8 POS N
months; POS N
hazard POS N
ratio, POS N
1.38; POS N
95% POS N
CI, POS N
1.08 POS N
to POS N
1.76; POS N
log-rank POS N
P POS N
= POS N
.009). POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Although POS N
time POS N
to POS N
definitive POS N
weight POS N
loss POS N
and POS N
time POS N
to POS N
definitive POS N
worsening POS N
of POS N
appetite POS N
favored POS N
DCF, POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

Pain-free POS N
survival POS N
and POS N
time POS N
to POS N
first POS N
cancer POS N
pain-related POS N
opioid POS N
intake POS N
were POS N
comparable. POS N

the POS N
results POS N
were POS N
not POS N
statistically POS N
significant. POS N

The POS N
addition POS N
of POS N
D POS N
to POS N
CF POS N
not POS N
only POS N
significantly POS N
improved POS N
clinical POS N
benefit POS N
but POS N
also POS N
improved POS N
quality POS N
of POS N
life, POS N
time POS N
to POS N
progression, POS N
and POS N
overall POS N
survival POS N
compared POS N
with POS N
CF. POS N

This POS N
randomized POS N
controlled POS N
trial POS N
revealed POS N
that POS N
TSM POS N
program POS N
appears POS N
to POS N
be POS N
a POS N
feasible POS N
and POS N
acceptable POS N
intervention POS N
and POS N
may POS N
be POS N
associated POS N
with POS N
short-term POS N
improvements POS N
in POS N
objective POS N
and POS N
subjective POS N
cognitive POS N
function POS N
as POS N
well POS N
as POS N
mental POS N
health POS N
and POS N
spirituality POS N
in POS N
breast POS N
cancer POS N
patients. POS N

Relative POS N
to POS N
the POS N
control POS N
group, POS N
women POS N
in POS N
the POS N
TSM POS N
group POS N
performed POS N
better POS N
on POS N
the POS N
verbal POS N
memory POS N
test POS N
(Rey POS N
Auditory POS N
Verbal POS N
Learning POS N
Test POS N
trial POS N
1) POS N
(p = 0.06) POS N
and POS N
the POS N
short-term POS N
memory POS N
and POS N
processing POS N
speed POS N
task POS N
(Digit POS N
Symbol) POS N
(p = 0.09) POS N
and POS N
reported POS N
improved POS N
cognitive POS N
function POS N
(p = 0.06), POS N
cognitive POS N
abilities POS N
(p = 0.08), POS N
mental POS N
health POS N
(p = 0.04), POS N
and POS N
spirituality POS N
(p = 0.05) POS N
at POS N
the POS N
end POS N
of POS N
treatment POS N
but POS N
not POS N
1 month POS N
later. POS N

Relative POS N
to POS N
the POS N
control POS N
group, POS N
women POS N
in POS N
the POS N
TSM POS N
group POS N
performed POS N
better POS N
on POS N
the POS N
verbal POS N
memory POS N
test POS N
(Rey POS N
Auditory POS N
Verbal POS N
Learning POS N
Test POS N
trial POS N
1) POS N
(p = 0.06) POS N
and POS N
the POS N
short-term POS N
memory POS N
and POS N
processing POS N
speed POS N
task POS N
(Digit POS N
Symbol) POS N
(p = 0.09) POS N
and POS N
reported POS N
improved POS N
cognitive POS N
function POS N
(p = 0.06), POS N
cognitive POS N
abilities POS N
(p = 0.08), POS N
mental POS N
health POS N
(p = 0.04), POS N
and POS N
spirituality POS N
(p = 0.05) POS N
at POS N
the POS N
end POS N
of POS N
treatment POS N
but POS N
not POS N
1 month POS N
later. POS N

This POS N
randomized POS N
controlled POS N
trial POS N
revealed POS N
that POS N
TSM POS N
program POS N
appears POS N
to POS N
be POS N
a POS N
feasible POS N
and POS N
acceptable POS N
intervention POS N
and POS N
may POS N
be POS N
associated POS N
with POS N
short-term POS N
improvements POS N
in POS N
objective POS N
and POS N
subjective POS N
cognitive POS N
function POS N
as POS N
well POS N
as POS N
mental POS N
health POS N
and POS N
spirituality POS N
in POS N
breast POS N
cancer POS N
patients. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

Median POS N
MFD POS N
time POS N
was POS N
reduced POS N
in POS N
the POS N
ERP POS N
group POS N
(3 POS N
days POS N
versus POS N
6 POS N
days POS N
with POS N
standard POS N
care; POS N
P POS N
< POS N
0·001), POS N
as POS N
was POS N
LOS POS N
(4 POS N
days POS N
versus POS N
7 POS N
days; POS N
P POS N
< POS N
0·001). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

The POS N
ERP POS N
significantly POS N
reduced POS N
the POS N
rate POS N
of POS N
medical POS N
complications POS N
(7 POS N
versus POS N
27 POS N
per POS N
cent; POS N
P POS N
= POS N
0·020), POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

but POS N
not POS N
surgical POS N
complications POS N
(15 POS N
versus POS N
11 POS N
per POS N
cent; POS N
P POS N
= POS N
0·612), POS N
readmissions POS N
(4 POS N
versus POS N
0 POS N
per POS N
cent; POS N
P POS N
= POS N
0·153) POS N
or POS N
mortality POS N
(both POS N
2 POS N
per POS N
cent; POS N
P POS N
= POS N
0·987). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

QoL POS N
over POS N
28 POS N
days POS N
was POS N
significantly POS N
better POS N
in POS N
the POS N
ERP POS N
group POS N
(P POS N
= POS N
0·002). POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
patient POS N
satisfaction. POS N

Patients POS N
treated POS N
in POS N
the POS N
ERP POS N
recovered POS N
faster, POS N
were POS N
discharged POS N
sooner, POS N
and POS N
had POS N
fewer POS N
medical-related POS N
complications POS N
and POS N
improved POS N
QoL. POS N

ERPs POS N
for POS N
open POS N
liver POS N
resection POS N
surgery POS N
are POS N
safe POS N
and POS N
effective. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Time POS N
to POS N
progression POS N
was POS N
longer POS N
for POS N
docetaxel POS N
patients POS N
than POS N
for POS N
best POS N
supportive POS N
care POS N
patients POS N
(10.6 POS N
v POS N
6.7 POS N
weeks, POS N
respectively; POS N
P POS N
<.001), POS N
as POS N
was POS N
median POS N
survival POS N
(7.0 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.047). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

The POS N
difference POS N
was POS N
more POS N
significant POS N
for POS N
docetaxel POS N
75 POS N
mg/m(2) POS N
patients, POS N
compared POS N
with POS N
corresponding POS N
best POS N
supportive POS N
care POS N
patients POS N
(7.5 POS N
v POS N
4.6 POS N
months; POS N
log-rank POS N
test, POS N
P POS N
=.010; POS N
1-year POS N
survival, POS N
37% POS N
v POS N
11%; POS N
chi(2) POS N
test, POS N
P POS N
=.003). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Febrile POS N
neutropenia POS N
occurred POS N
in POS N
11 POS N
patients POS N
treated POS N
with POS N
docetaxel POS N
100 POS N
mg/m(2), POS N
three POS N
of POS N
whom POS N
died, POS N
and POS N
in POS N
one POS N
patient POS N
treated POS N
with POS N
docetaxel POS N
75 POS N
mg/m(2). POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Grade POS N
3 POS N
or POS N
4 POS N
nonhematologic POS N
toxicity, POS N
with POS N
the POS N
exception POS N
of POS N
diarrhea, POS N
occurred POS N
at POS N
a POS N
similar POS N
rate POS N
in POS N
both POS N
the POS N
docetaxel POS N
and POS N
best POS N
supportive POS N
care POS N
groups. POS N

at POS N
a POS N
dose POS N
of POS N
75 POS N
mg/m(2), POS N
the POS N
benefits POS N
of POS N
docetaxel POS N
therapy POS N
outweigh POS N
the POS N
risks. POS N

Treatment POS N
with POS N
docetaxel POS N
is POS N
associated POS N
with POS N
significant POS N
prolongation POS N
of POS N
survival, POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

In POS N
a POS N
randomized POS N
clinical POS N
trial POS N
in POS N
patients POS N
with POS N
advanced POS N
non-small-cell POS N
lung POS N
cancer POS N
(NSCLC), POS N
infusion POS N
with POS N
adenosine POS N
5'-triphosphate POS N
(ATP) POS N
inhibited POS N
loss POS N
of POS N
body POS N
weight POS N
and POS N
quality POS N
of POS N
life. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
change POS N
in POS N
body POS N
composition POS N
over POS N
the POS N
28-week POS N
follow-up POS N
period POS N
was POS N
found POS N
in POS N
the POS N
ATP POS N
group, POS N
whereas, POS N
per POS N
4 POS N
weeks, POS N
the POS N
control POS N
group POS N
lost POS N
0.6 POS N
kg POS N
of POS N
FM POS N
(P POS N
=.004), POS N
0.5 POS N
kg POS N
of POS N
FFM POS N
(P POS N
=.02), POS N
1.8% POS N
of POS N
arm POS N
muscle POS N
area POS N
(P POS N
=.02), POS N
and POS N
0.6% POS N
of POS N
BCM/kg POS N
body POS N
weight POS N
(P POS N
=.054) POS N
and POS N
decreased POS N
568 POS N
KJ/d POS N
in POS N
energy POS N
intake POS N
(P POS N
=.0001). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

Appetite POS N
also POS N
remained POS N
stable POS N
in POS N
the POS N
ATP POS N
group POS N
but POS N
decreased POS N
significantly POS N
in POS N
the POS N
control POS N
group POS N
(P POS N
=.0004). POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

No POS N
significant POS N
differences POS N
in POS N
REE POS N
between POS N
the POS N
ATP POS N
and POS N
control POS N
groups POS N
were POS N
observed. POS N

These POS N
effects POS N
are POS N
partly POS N
ascribed POS N
to POS N
maintenance POS N
of POS N
energy POS N
intake. POS N

The POS N
inhibition POS N
of POS N
weight POS N
loss POS N
by POS N
ATP POS N
infusions POS N
in POS N
patients POS N
with POS N
advanced POS N
NSCLC POS N
is POS N
attributed POS N
to POS N
counteracting POS N
the POS N
loss POS N
of POS N
both POS N
metabolically POS N
active POS N
and POS N
inactive POS N
tissues. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

Significantly POS N
fewer POS N
EPO POS N
patients POS N
than POS N
BSC POS N
patients POS N
with POS N
initial POS N
Hb POS N
levels POS N
>9.7 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl POS N
required POS N
transfusions. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

EPO POS N
maintained POS N
Hb POS N
levels POS N
throughout POS N
the POS N
study POS N
for POS N
patients POS N
with POS N
Hb POS N
levels POS N
>11.3 POS N
g/dl POS N
to POS N
< POS N
or POS N
=12.1 POS N
g/dl, POS N
compared POS N
with POS N
a POS N
decrease POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

For POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
for POS N
whom POS N
the POS N
mean POS N
changes POS N
from POS N
baseline POS N
to POS N
last POS N
assessment POS N
were POS N
measured POS N
by POS N
the POS N
Cancer POS N
Linear POS N
Analogue POS N
Scale POS N
assessments POS N
of POS N
energy POS N
and POS N
overall POS N
QOL POS N
as POS N
well POS N
as POS N
by POS N
the POS N
Functional POS N
Assessment POS N
of POS N
Cancer POS N
Therapy POS N
(FACT)-Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscale, POS N
QOL POS N
scores POS N
were POS N
significantly POS N
greater POS N
with POS N
EPO POS N
than POS N
with POS N
BSC. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

QOL POS N
declined POS N
in POS N
patients POS N
receiving POS N
BSC, POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

the POS N
mean POS N
decreases POS N
in POS N
QOL POS N
scores POS N
were POS N
greater POS N
for POS N
BSC POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
compared POS N
with POS N
the POS N
overall POS N
BSC POS N
group. POS N

This POS N
study POS N
supports POS N
the POS N
positive POS N
effects POS N
of POS N
early POS N
intervention POS N
when POS N
analyzed POS N
according POS N
to POS N
initial POS N
Hb POS N
value. POS N

In POS N
patients POS N
with POS N
cancer POS N
receiving POS N
platinum-based POS N
chemotherapy POS N
and POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl, POS N
early POS N
intervention POS N
with POS N
EPO POS N
reduces POS N
transfusions, POS N
maintains POS N
Hb POS N
level, POS N
and POS N
maintains POS N
or POS N
improves POS N
QOL. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

The POS N
trial POS N
had POS N
to POS N
be POS N
stopped POS N
prematurely POS N
due POS N
to POS N
insufficient POS N
patient POS N
recruitment. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
amount POS N
of POS N
blood POS N
loss POS N
between POS N
both POS N
groups: POS N
LAP POS N
261.5 ± 195.4 ml, POS N
CON POS N
228.1 ± 119.5 ml. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

Laparoscopic POS N
surgery POS N
was POS N
superior POS N
regarding POS N
the POS N
length POS N
of POS N
skin POS N
incision; POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

the POS N
conventional POS N
approach POS N
was POS N
superior POS N
in POS N
duration POS N
of POS N
operation. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
were POS N
no POS N
discrepancies POS N
in POS N
length POS N
of POS N
hospital POS N
stay, POS N
postoperative POS N
pain, POS N
bowel POS N
function, POS N
and POS N
quality POS N
of POS N
life POS N
between POS N
both POS N
approaches. POS N

The POS N
LAP POS N
approach POS N
is POS N
feasible POS N
for POS N
restorative POS N
proctocolectomy, POS N
and POS N
IPAA POS N
seems POS N
at POS N
least POS N
as POS N
safe POS N
as POS N
CON POS N
surgery. POS N

There POS N
was POS N
no POS N
difference POS N
with POS N
respect POS N
to POS N
blood POS N
loss POS N
between POS N
the POS N
LAP POS N
and POS N
the POS N
CON POS N
group. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Differences POS N
in POS N
mean POS N
QOL POS N
change POS N
scores POS N
from POS N
baseline POS N
to POS N
study POS N
end POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
BSC POS N
were POS N
3.17 POS N
points POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
9.90 POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
subscale, POS N
and POS N
7.30 POS N
for POS N
the POS N
FACT-An POS N
Anemia POS N
subscale. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

This POS N
was POS N
equivalent POS N
to POS N
corrections POS N
in POS N
QOL POS N
deficits POS N
attributable POS N
to POS N
epoetin POS N
alfa POS N
of POS N
97.3%, POS N
40.7%, POS N
and POS N
38.0% POS N
for POS N
the POS N
FACT-General POS N
Total, POS N
FACT-An POS N
Fatigue, POS N
and POS N
FACT-An POS N
Anemia POS N
subscale POS N
scores, POS N
respectively, POS N
versus POS N
BSC. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

A POS N
somewhat POS N
greater POS N
QOL POS N
benefit POS N
was POS N
observed POS N
for POS N
the POS N
FACT-An POS N
Fatigue POS N
and POS N
FACT-An POS N
Anemia POS N
subscales POS N
in POS N
the POS N
subset POS N
of POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Early POS N
treatment POS N
with POS N
epoetin POS N
alfa POS N
to POS N
correct POS N
anemia POS N
improved POS N
QOL POS N
in POS N
a POS N
statistically POS N
significant POS N
and POS N
clinically POS N
meaningful POS N
way, POS N
and POS N
improvements POS N
were POS N
greater POS N
in POS N
patients POS N
with POS N
baseline POS N
Hb POS N
levels POS N
>10.5 POS N
g/dl. POS N

Patients POS N
in POS N
this POS N
study POS N
had POS N
impaired POS N
QOL POS N
compared POS N
with POS N
population POS N
norms. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
TTP POS N
in POS N
the POS N
test POS N
group POS N
was POS N
prolonged POS N
for POS N
23 POS N
days POS N
when POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
control POS N
group, POS N
with POS N
insignificant POS N
difference POS N
(87 POS N
days POS N
vs POS N
64 POS N
days, POS N
P=0.063). POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
scores POS N
of POS N
domains POS N
in POS N
EORTC POS N
QLQ-LC43 POS N
were POS N
statistically POS N
significantly POS N
better POS N
in POS N
the POS N
test POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P<0.05) POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

The POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
had POS N
equivalent POS N
efficacy POS N
on POS N
TTP POS N
when POS N
compared POS N
with POS N
single-agent POS N
maintenance POS N
chemotherapy POS N
regimen. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

It POS N
is POS N
necessary POS N
to POS N
enlarge POS N
the POS N
sample POS N
size POS N
to POS N
further POS N
confirm POS N
the POS N
therapeutic POS N
efficacy POS N
of POS N
CM POS N
comprehensive POS N
regimen POS N
as POS N
MT POS N
in POS N
treatment POS N
of POS N
patients POS N
with POS N
advanced POS N
NSCLC. POS N

It POS N
was POS N
advantageous POS N
over POS N
improving POS N
the POS N
QOL. POS N

except POS N
cognitive POS N
and POS N
social POS N
functions, POS N
the POS N
symptoms POS N
of POS N
dysphagia POS N
and POS N
pain POS N
in POS N
other POS N
parts. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
choice POS N
of POS N
reconstruction POS N
after POS N
gastrectomy POS N
and POS N
the POS N
significance POS N
of POS N
remaining POS N
reservoir POS N
function POS N
is POS N
a POS N
matter POS N
of POS N
controversy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

The POS N
postoperative POS N
complication POS N
and POS N
mortality POS N
rates POS N
were POS N
similar POS N
in POS N
all POS N
treatment POS N
groups, POS N
with POS N
few POS N
serious POS N
complications POS N
recorded. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Irrespective POS N
of POS N
type POS N
of POS N
treatment, POS N
the POS N
patients POS N
suffered POS N
from POS N
alimentary POS N
symptoms POS N
and POS N
functional POS N
limitations POS N
in POS N
everyday POS N
life, POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

whereas POS N
their POS N
mental POS N
well-being POS N
improved POS N
after POS N
surgery. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
who POS N
underwent POS N
subtotal POS N
gastrectomy POS N
had POS N
the POS N
best POS N
outcome, POS N
especially POS N
with POS N
respect POS N
to POS N
complaints POS N
of POS N
diarrhea. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

Patients POS N
given POS N
a POS N
gastric POS N
substitute POS N
after POS N
gastrectomy POS N
showed POS N
no POS N
difference POS N
from POS N
those POS N
who POS N
had POS N
only POS N
a POS N
total POS N
gastrectomy. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

We POS N
conclude POS N
that POS N
despite POS N
significant POS N
unfavorable POS N
consequences POS N
that POS N
follow POS N
gastrectomy, POS N
patients POS N
recover POS N
with POS N
an POS N
improved POS N
mental POS N
status. POS N

a POS N
subtotal POS N
gastrectomy POS N
has POS N
advantages POS N
that POS N
must POS N
be POS N
considered POS N
when POS N
the POS N
procedure POS N
is POS N
clinically POS N
feasible. POS N

A POS N
pouch POS N
reconstruction POS N
after POS N
total POS N
gastrectomy POS N
does POS N
not POS N
improve POS N
quality POS N
of POS N
life, POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

At POS N
12 POS N
months, POS N
significant POS N
intervention POS N
effects POS N
were POS N
observed POS N
for POS N
moderate POS N
physical POS N
activity POS N
(28.5 POS N
minutes; POS N
P POS N
= POS N
.003), POS N
body POS N
mass POS N
index POS N
(-0.9 POS N
kg/m(2); POS N
P POS N
= POS N
.001), POS N
energy POS N
from POS N
total POS N
fat POS N
(-7.0%; POS N
P POS N
= POS N
.006), POS N
and POS N
energy POS N
from POS N
saturated POS N
fat POS N
(-2.8%; POS N
P POS N
= POS N
.016). POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

A POS N
significant POS N
intervention POS N
effect POS N
was POS N
reported POS N
for POS N
vegetable POS N
intake POS N
(0.4 POS N
servings POS N
per POS N
day; POS N
P POS N
= POS N
.001) POS N
at POS N
6 POS N
months. POS N

The POS N
CanChange POS N
intervention POS N
was POS N
effective POS N
for POS N
improving POS N
physical POS N
activity, POS N
dietary POS N
habits, POS N
and POS N
body POS N
mass POS N
index POS N
in POS N
colorectal POS N
cancer POS N
survivors. POS N

No POS N
significant POS N
group POS N
differences POS N
were POS N
found POS N
at POS N
6 POS N
or POS N
12 POS N
months POS N
for POS N
HRQoL, POS N
cancer-related POS N
fatigue, POS N
fruit, POS N
fiber, POS N
or POS N
alcohol POS N
intake, POS N
or POS N
smoking. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

During POS N
the POS N
CEE POS N
plus POS N
MPA POS N
intervention POS N
phase, POS N
the POS N
numbers POS N
of POS N
CHD POS N
cases POS N
were POS N
196 POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
159 POS N
for POS N
placebo POS N
(hazard POS N
ratio POS N
[HR], POS N
1.18; POS N
95% POS N
CI, POS N
0.95-1.45) POS N
and POS N
206 POS N
vs POS N
155, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
1.24; POS N
95% POS N
CI, POS N
1.01-1.53). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Other POS N
risks POS N
included POS N
increased POS N
stroke, POS N
pulmonary POS N
embolism, POS N
dementia POS N
(in POS N
women POS N
aged POS N
≥65 POS N
years), POS N
gallbladder POS N
disease, POS N
and POS N
urinary POS N
incontinence; POS N
benefits POS N
included POS N
decreased POS N
hip POS N
fractures, POS N
diabetes, POS N
and POS N
vasomotor POS N
symptoms. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Most POS N
risks POS N
and POS N
benefits POS N
dissipated POS N
postintervention, POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

although POS N
some POS N
elevation POS N
in POS N
breast POS N
cancer POS N
risk POS N
persisted POS N
during POS N
cumulative POS N
follow-up POS N
(434 POS N
cases POS N
for POS N
CEE POS N
plus POS N
MPA POS N
vs POS N
323 POS N
for POS N
placebo; POS N
HR, POS N
1.28 POS N
[95% POS N
CI, POS N
1.11-1.48]). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

The POS N
risks POS N
and POS N
benefits POS N
were POS N
more POS N
balanced POS N
during POS N
the POS N
CEE POS N
alone POS N
intervention POS N
with POS N
204 POS N
CHD POS N
cases POS N
for POS N
CEE POS N
alone POS N
vs POS N
222 POS N
cases POS N
for POS N
placebo POS N
(HR, POS N
0.94; POS N
95% POS N
CI, POS N
0.78-1.14) POS N
and POS N
104 POS N
vs POS N
135, POS N
respectively, POS N
for POS N
invasive POS N
breast POS N
cancer POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.61-1.02); POS N
cumulatively, POS N
there POS N
were POS N
168 POS N
vs POS N
216, POS N
respectively, POS N
cases POS N
of POS N
breast POS N
cancer POS N
diagnosed POS N
(HR, POS N
0.79; POS N
95% POS N
CI, POS N
0.65-0.97). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

For POS N
CEE POS N
alone, POS N
younger POS N
women POS N
(aged POS N
50-59 POS N
years) POS N
had POS N
more POS N
favorable POS N
results POS N
for POS N
all-cause POS N
mortality, POS N
myocardial POS N
infarction, POS N
and POS N
the POS N
global POS N
index POS N
(nominal POS N
P < .05 POS N
for POS N
trend POS N
by POS N
age). POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Absolute POS N
risks POS N
of POS N
adverse POS N
events POS N
(measured POS N
by POS N
the POS N
global POS N
index) POS N
per POS N
10,000 POS N
women POS N
annually POS N
taking POS N
CEE POS N
plus POS N
MPA POS N
ranged POS N
from POS N
12 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
38 POS N
for POS N
ages POS N
of POS N
70-79 POS N
years; POS N
for POS N
women POS N
taking POS N
CEE POS N
alone, POS N
from POS N
19 POS N
fewer POS N
cases POS N
for POS N
ages POS N
of POS N
50-59 POS N
years POS N
to POS N
51 POS N
excess POS N
cases POS N
for POS N
ages POS N
of POS N
70-79 POS N
years. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Menopausal POS N
hormone POS N
therapy POS N
has POS N
a POS N
complex POS N
pattern POS N
of POS N
risks POS N
and POS N
benefits. POS N

although POS N
it POS N
is POS N
appropriate POS N
for POS N
symptom POS N
management POS N
in POS N
some POS N
women. POS N

Findings POS N
from POS N
the POS N
intervention POS N
and POS N
extended POS N
postintervention POS N
follow-up POS N
of POS N
the POS N
2 POS N
WHI POS N
hormone POS N
therapy POS N
trials POS N
do POS N
not POS N
support POS N
use POS N
of POS N
this POS N
therapy POS N
for POS N
chronic POS N
disease POS N
prevention, POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Significantly POS N
more POS N
patients POS N
recorded POS N
improvements POS N
in POS N
HRQoL POS N
and POS N
symptoms POS N
with POS N
gefitinib POS N
in POS N
the POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(n POS N
= POS N
259; POS N
FACT-L POS N
70.2% POS N
versus POS N
44.5%; POS N
odds POS N
ratio, POS N
3.01 POS N
[95% POS N
confidence POS N
interval, POS N
1.79-5.07]; POS N
p POS N
< POS N
0.001; POS N
TOI POS N
70.2% POS N
versus POS N
38.3%; POS N
3.96 POS N
[2.33-6.71]; POS N
p POS N
< POS N
0.001; POS N
LCS POS N
75.6% POS N
versus POS N
53.9%; POS N
2.70 POS N
[1.58-4.62]; POS N
p POS N
< POS N
0.001), POS N
and POS N
with POS N
carboplatin/paclitaxel POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(n POS N
= POS N
169; POS N
FACT-L POS N
14.6% POS N
versus POS N
36.3%; POS N
odds POS N
ratio, POS N
0.31 POS N
[0.15-0.65]; POS N
p POS N
= POS N
0.002; POS N
TOI POS N
12.4% POS N
versus POS N
28.8%; POS N
0.35 POS N
[0.16-0.79]; POS N
p POS N
= POS N
0.011; POS N
LCS POS N
20.2% POS N
versus POS N
47.5%; POS N
0.28 POS N
[0.14-0.55]; POS N
p POS N
< POS N
0.001). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-worsening POS N
(months) POS N
FACT-L POS N
score POS N
was POS N
longer POS N
with POS N
gefitinib POS N
versus POS N
carboplatin/paclitaxel POS N
for POS N
the POS N
overall POS N
population POS N
(8.3 POS N
versus POS N
2.5) POS N
and POS N
EGFR POS N
mutation-positive POS N
subgroup POS N
(15.6 POS N
versus POS N
3.0), POS N
and POS N
similar POS N
for POS N
both POS N
treatments POS N
in POS N
the POS N
EGFR POS N
mutation-negative POS N
subgroup POS N
(1.4 POS N
versus POS N
1.4). POS N

HRQoL POS N
and POS N
symptom POS N
endpoints POS N
were POS N
consistent POS N
with POS N
efficacy POS N
outcomes POS N
in POS N
IPASS POS N
and POS N
favored POS N
gefitinib POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
and POS N
carboplatin/paclitaxel POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-negative POS N
tumors. POS N

Median POS N
time-to-improvement POS N
with POS N
gefitinib POS N
was POS N
8 POS N
days POS N
in POS N
patients POS N
with POS N
EGFR POS N
mutation-positive POS N
tumors POS N
who POS N
improved. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

After POS N
a POS N
median POS N
follow-up POS N
time POS N
of POS N
9.64 POS N
months, POS N
incidence POS N
rates POS N
of POS N
grades POS N
2-4 POS N
acute POS N
diarrhea POS N
were POS N
similar POS N
in POS N
both POS N
groups POS N
(49% POS N
placebo POS N
vs POS N
44% POS N
LAO; POS N
P POS N
= POS N
.21). POS N

In POS N
this POS N
study, POS N
the POS N
prophylactic POS N
use POS N
of POS N
LAO POS N
did POS N
not POS N
prevent POS N
the POS N
incidence POS N
or POS N
reduce POS N
the POS N
severity POS N
of POS N
diarrhea POS N
and POS N
had POS N
no POS N
notable POS N
impact POS N
on POS N
patient-reported POS N
bowel POS N
function POS N
or POS N
QoL. POS N

No POS N
statistically POS N
significant POS N
treatment POS N
differences POS N
in POS N
chemotherapy POS N
or POS N
radiation POS N
delivery, POS N
medical POS N
resource POS N
utilization, POS N
patient-reported POS N
bowel POS N
function, POS N
or POS N
QoL POS N
were POS N
observed. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
the POS N
context POS N
of POS N
chronic POS N
physical POS N
illness, POS N
such POS N
as POS N
breast POS N
cancer, POS N
depression POS N
is POS N
associated POS N
with POS N
increased POS N
morbidity, POS N
longer POS N
periods POS N
of POS N
hospitalization, POS N
and POS N
greater POS N
overall POS N
disability. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

After POS N
8-weeks POS N
treatment, POS N
depressive POS N
symptomatology POS N
had POS N
improved POS N
markedly POS N
and POS N
to POS N
a POS N
similar POS N
extent POS N
in POS N
both POS N
groups POS N
on POS N
the POS N
Montgomery POS N
Asberg POS N
Depression POS N
Rating POS N
Scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Clinical POS N
global POS N
impression POS N
(CGI) POS N
Global POS N
improvement POS N
and POS N
Patient POS N
global POS N
evaluation POS N
scales POS N
indicated POS N
that POS N
patients POS N
were POS N
minimally POS N
to POS N
much POS N
improved POS N
at POS N
study POS N
endpoint: POS N
a POS N
change POS N
from POS N
moderately/mildly POS N
ill POS N
to POS N
borderline POS N
ill POS N
on POS N
the POS N
CGI POS N
severity POS N
of POS N
Illness POS N
scale. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

A POS N
steady POS N
improvement POS N
in POS N
quality POS N
of POS N
life POS N
was POS N
also POS N
observed POS N
in POS N
both POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

There POS N
were POS N
no POS N
clinically POS N
significant POS N
differences POS N
between POS N
the POS N
groups. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

In POS N
total, POS N
47 POS N
(53.4%) POS N
patients POS N
in POS N
the POS N
paroxetine POS N
group POS N
and POS N
53 POS N
(59.6%) POS N
patients POS N
in POS N
the POS N
amitriptyline POS N
group POS N
had POS N
adverse POS N
experiences, POS N
the POS N
most POS N
common POS N
of POS N
which POS N
were POS N
the POS N
well-recognized POS N
side-effects POS N
of POS N
the POS N
antidepressant POS N
medications POS N
or POS N
chemotherapy. POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

Anticholinergic POS N
effects POS N
were POS N
almost POS N
twice POS N
as POS N
frequent POS N
in POS N
the POS N
amitriptyline POS N
group POS N
(19.1%) POS N
compared POS N
with POS N
paroxetine POS N
(11.4%). POS N

Prompt POS N
diagnosis POS N
and POS N
effective POS N
treatment POS N
is, POS N
therefore, POS N
essential. POS N

paroxetine POS N
is POS N
a POS N
suitable POS N
alternative POS N
to POS N
amitriptyline POS N
for POS N
the POS N
treatment POS N
of POS N
depression POS N
in POS N
patients POS N
with POS N
breast POS N
cancer. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
most POS N
favorable POS N
effect POS N
was POS N
observed POS N
in POS N
patients POS N
with POS N
low POS N
hepatic POS N
tumor POS N
load POS N
and POS N
resected POS N
primary POS N
tumor. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Seven POS N
and POS N
nine POS N
deaths POS N
were POS N
observed POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups, POS N
respectively. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
HR POS N
for POS N
overall POS N
survival POS N
was POS N
0.81 POS N
(95% POS N
CI, POS N
0.30 POS N
to POS N
2.18). POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Octreotide POS N
LAR POS N
significantly POS N
lengthens POS N
time POS N
to POS N
tumor POS N
progression POS N
compared POS N
with POS N
placebo POS N
in POS N
patients POS N
with POS N
functionally POS N
active POS N
and POS N
inactive POS N
metastatic POS N
midgut POS N
NETs. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Because POS N
of POS N
the POS N
low POS N
number POS N
of POS N
observed POS N
deaths, POS N
survival POS N
analysis POS N
was POS N
not POS N
confirmatory. POS N

After POS N
6 POS N
months POS N
of POS N
treatment, POS N
stable POS N
disease POS N
was POS N
observed POS N
in POS N
66.7% POS N
of POS N
patients POS N
in POS N
the POS N
octreotide POS N
LAR POS N
group POS N
and POS N
37.2% POS N
of POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Median POS N
time POS N
to POS N
tumor POS N
progression POS N
in POS N
the POS N
octreotide POS N
LAR POS N
and POS N
placebo POS N
groups POS N
was POS N
14.3 POS N
and POS N
6 POS N
months, POS N
respectively POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
0.34; POS N
95% POS N
CI, POS N
0.20 POS N
to POS N
0.59; POS N
P POS N
= POS N
.000072). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
OS POS N
(p=0.992). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
a POS N
significant POS N
decrease POS N
in POS N
pain POS N
scores POS N
from POS N
baseline POS N
to POS N
post POS N
cycles POS N
2 POS N
and POS N
3 POS N
(p=0.025 POS N
and POS N
p=0.002, POS N
respectively). POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

No POS N
difference POS N
was POS N
observed POS N
in POS N
hospitalization POS N
rate, POS N
blood POS N
transfusions, POS N
antibiotics POS N
administration POS N
and POS N
non-haematological POS N
toxicity. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistical POS N
difference POS N
in POS N
the POS N
number POS N
of POS N
cycles POS N
administered POS N
(arms POS N
A, POS N
B POS N
and POS N
D: POS N
median POS N
2 POS N
cycles POS N
and POS N
arm POS N
C: POS N
median POS N
3 POS N
cycles) POS N
and POS N
no POS N
difference POS N
in POS N
RR: POS N
arm POS N
A=6%, POS N
arm POS N
B=6%, POS N
arm POS N
C=10%, POS N
and POS N
arm POS N
D=0%. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
grade POS N
3/4 POS N
neutropenia POS N
and POS N
thrombocytopenia POS N
between POS N
the POS N
four POS N
arms. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Median POS N
survival POS N
and POS N
6-month POS N
survival POS N
were POS N
61, POS N
86, POS N
88 POS N
and POS N
97 POS N
days POS N
and POS N
29%, POS N
33%, POS N
21% POS N
and POS N
26% POS N
for POS N
arms POS N
A, POS N
B, POS N
C, POS N
and POS N
D, POS N
respectively. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Clinical POS N
efficacy POS N
of POS N
docetaxel POS N
was POS N
observed POS N
at POS N
all POS N
dose POS N
levels. POS N

the POS N
median POS N
survival POS N
observed POS N
is POS N
shorter POS N
than POS N
historical POS N
data POS N
and POS N
do POS N
not POS N
support POS N
further POS N
evaluation POS N
of POS N
these POS N
doses POS N
of POS N
single POS N
agent POS N
docetaxel POS N
in POS N
this POS N
population. POS N

Higher POS N
dose POS N
levels POS N
were POS N
not POS N
associated POS N
with POS N
increased POS N
toxicities, POS N
use POS N
of POS N
IV POS N
antibiotics POS N
or POS N
hospitalization POS N
rates. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

After POS N
1 POS N
mo, POS N
44.1% POS N
(26 POS N
of POS N
59) POS N
of POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A, POS N
while POS N
20.3% POS N
(12 POS N
of POS N
59) POS N
were POS N
continent POS N
in POS N
group POS N
B POS N
(p=0.018). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

At POS N
3 POS N
mo, POS N
59.3% POS N
(35 POS N
of POS N
59) POS N
and POS N
37.3% POS N
(22 POS N
of POS N
59) POS N
patients POS N
were POS N
continent POS N
in POS N
group POS N
A POS N
and POS N
group POS N
B, POS N
respectively POS N
(p=0.028). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

The POS N
ICS POS N
male POS N
SF POS N
mean POS N
score POS N
showed POS N
better POS N
results POS N
in POS N
group POS N
A POS N
than POS N
in POS N
group POS N
B POS N
patients POS N
at POS N
both POS N
1 POS N
mo POS N
(14.6 POS N
vs POS N
18.3) POS N
and POS N
3 POS N
mo POS N
(8.1 POS N
vs POS N
12.2) POS N
after POS N
RP POS N
(p=0.002). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

In POS N
age-adjusted POS N
logistic POS N
regression POS N
analyses, POS N
patients POS N
who POS N
performed POS N
preoperative POS N
PFME POS N
had POS N
a POS N
0.41-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
1 POS N
mo POS N
after POS N
RP POS N
and POS N
a POS N
0.38-fold POS N
lower POS N
risk POS N
of POS N
being POS N
incontinent POS N
3 POS N
mo POS N
after POS N
RP POS N
(p≤0.001). POS N

Further POS N
studies POS N
are POS N
needed POS N
to POS N
corroborate POS N
our POS N
results. POS N

Preoperative POS N
PFME POS N
may POS N
improve POS N
early POS N
continence POS N
and POS N
QoL POS N
outcomes POS N
after POS N
RP. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

Results POS N
were POS N
correlated POS N
with POS N
previously POS N
reported POS N
objective POS N
sensibility POS N
outcomes. POS N

This POS N
study POS N
demonstrates POS N
that POS N
innervation POS N
of POS N
free POS N
TRAM POS N
flaps POS N
used POS N
for POS N
breast POS N
reconstruction POS N
not POS N
only POS N
improves POS N
sensibility POS N
but POS N
also POS N
has POS N
a POS N
positive POS N
effect POS N
on POS N
patient-rated POS N
quality POS N
of POS N
life. POS N

There POS N
was POS N
a POS N
statistically POS N
significant POS N
improvement POS N
in POS N
all POS N
three POS N
measures POS N
in POS N
patients POS N
who POS N
were POS N
randomized POS N
to POS N
receive POS N
innervated POS N
free POS N
TRAM POS N
flaps POS N
compared POS N
with POS N
those POS N
receiving POS N
noninnervated POS N
flaps. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

This POS N
may POS N
lead POS N
to POS N
reduced POS N
distress POS N
and POS N
fatigue, POS N
and POS N
consequently POS N
improved POS N
QoL POS N
of POS N
cancer POS N
survivors. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

In POS N
addition POS N
to POS N
physical POS N
activity, POS N
future POS N
interventions POS N
should POS N
target POS N
self-efficacy POS N
and POS N
mastery. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
beneficial POS N
effect POS N
of POS N
group-based POS N
physical POS N
exercise POS N
on POS N
QoL POS N
was POS N
mediated POS N
by POS N
increased POS N
physical POS N
activity, POS N
general POS N
self-efficacy POS N
and POS N
mastery, POS N
and POS N
subsequent POS N
reductions POS N
in POS N
fatigue POS N
and POS N
distress. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

increased POS N
physical POS N
activity POS N
was POS N
directly POS N
associated POS N
with POS N
improved POS N
QoL POS N
(β POS N
= POS N
3.37, POS N
95%CI POS N
= POS N
1.01;5.54). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

Reductions POS N
in POS N
fatigue POS N
(β POS N
= POS N
-1.33, POS N
95%CI =-1.85;-0.83) POS N
and POS N
distress POS N
(β POS N
= POS N
-0.86, POS N
95%CI POS N
= POS N
-1.25;-0.52) POS N
were POS N
associated POS N
with POS N
improved POS N
QoL. POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

The POS N
intervention POS N
had POS N
a POS N
borderline POS N
significant POS N
direct POS N
effect POS N
on POS N
reduced POS N
distress POS N
(β POS N
= POS N
-1.32, POS N
95%CI POS N
= POS N
-2.68;0.11), POS N
and POS N
a POS N
significant POS N
indirect POS N
effect POS N
via POS N
increased POS N
general POS N
self-efficacy POS N
and POS N
mastery POS N
(β POS N
= POS N
-1.06, POS N
95%CI POS N
= POS N
-1.89;-0.38). POS N

The POS N
intervention POS N
was POS N
associated POS N
with POS N
increased POS N
physical POS N
activity POS N
(β POS N
= POS N
0.46, POS N
95% POS N
confidence POS N
interval POS N
(CI) = POS N
0.14;0.59), POS N
general POS N
self-efficacy POS N
(β POS N
= POS N
2.41, POS N
95%CI POS N
= POS N
0.35;4.73), POS N
and POS N
mastery POS N
(β POS N
= POS N
1.75, POS N
95%CI POS N
= POS N
0.36;2.78). POS N

the POS N
intervention POS N
had POS N
both POS N
a POS N
direct POS N
effect POS N
on POS N
fatigue POS N
(β POS N
= -1.09, POS N
95%CI POS N
= -2.12;0.01), POS N
and POS N
an POS N
indirect POS N
effect POS N
(β POS N
= -0.54, POS N
95%CI POS N
= -1.00;-0.21) POS N
via POS N
physical POS N
activity POS N
(β POS N
= -0.29, POS N
95%CI POS N
= POS N
-0.64;-0.07) POS N
and POS N
general POS N
self-efficacy POS N
(β POS N
= -0.25, POS N
95%CI POS N
= -0.61;-0.05). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

RT POS N
was POS N
then POS N
associated POS N
with POS N
increased POS N
breast POS N
symptoms POS N
and POS N
with POS N
greater POS N
(self-reported) POS N
fatigue, POS N
but POS N
with POS N
lower POS N
levels POS N
of POS N
insomnia POS N
and POS N
endocrine POS N
side POS N
effects. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

These POS N
statistically POS N
significant POS N
differences POS N
in POS N
breast POS N
symptoms POS N
persisted POS N
for POS N
up POS N
to POS N
5 POS N
years POS N
after POS N
RT POS N
[mean POS N
difference, POS N
RT POS N
was POS N
5.27 POS N
units POS N
greater POS N
than POS N
no POS N
RT, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
of POS N
1.46 POS N
to POS N
9.07], POS N
with POS N
similar, POS N
though POS N
non-significant, POS N
trends POS N
in POS N
insomnia. POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

No POS N
significant POS N
difference POS N
was POS N
found POS N
in POS N
the POS N
overall POS N
quality POS N
of POS N
life POS N
measure, POS N
with POS N
the POS N
no POS N
RT POS N
group POS N
having POS N
0.36 POS N
units POS N
greater POS N
quality POS N
of POS N
life POS N
than POS N
the POS N
RT POS N
group POS N
(95% POS N
CI POS N
-5.09 POS N
to POS N
5.81). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

Breast POS N
RT POS N
is POS N
tolerated POS N
well POS N
by POS N
most POS N
older POS N
breast POS N
cancer POS N
patients POS N
without POS N
impairing POS N
their POS N
overall POS N
health-related POS N
quality POS N
of POS N
life POS N
(HRQoL). POS N

Further POS N
economic POS N
modelling POS N
on POS N
the POS N
longer-term POS N
costs POS N
and POS N
consequences POS N
of POS N
omitting POS N
RT POS N
is POS N
required. POS N

our POS N
results POS N
show POS N
that POS N
the POS N
addition POS N
of POS N
RT POS N
does POS N
not POS N
impair POS N
overall POS N
quality POS N
of POS N
life. POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

Overall, POS N
the POS N
mean POS N
global POS N
QoL POS N
score POS N
improved POS N
during POS N
chemotherapy POS N
by POS N
7·2 POS N
points POS N
(SD POS N
24·4) POS N
when POS N
analysed POS N
for POS N
all POS N
women POS N
with POS N
data POS N
at POS N
baseline POS N
and POS N
week POS N
18. POS N

Bevacizumab POS N
continuation POS N
treatment POS N
seems POS N
to POS N
be POS N
associated POS N
with POS N
a POS N
small POS N
but POS N
clinically POS N
significant POS N
decrement POS N
in POS N
QoL POS N
compared POS N
with POS N
standard POS N
treatment POS N
for POS N
women POS N
with POS N
ovarian POS N
cancer. POS N

The POS N
mean POS N
global POS N
QoL POS N
score POS N
at POS N
54 POS N
weeks POS N
was POS N
higher POS N
in POS N
the POS N
standard POS N
chemotherapy POS N
group POS N
than POS N
in POS N
the POS N
bevacizumab POS N
group POS N
(76·1 POS N
[SD POS N
18·2] POS N
vs POS N
69·7 POS N
[19·1] POS N
points; POS N
difference POS N
6·4 POS N
points, POS N
95% POS N
CI POS N
3·7-9·0, POS N
p<0·0001). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

For POS N
intervention POS N
and POS N
control POS N
groups POS N
respectively, POS N
mean POS N
catheter POS N
duration POS N
was POS N
11.74 POS N
d POS N
and POS N
12.74 POS N
d POS N
(p=0.451); POS N
leakage POS N
on POS N
cystogram POS N
was POS N
present POS N
in POS N
six POS N
and POS N
eight POS N
cases POS N
(p=0.28); POS N
and POS N
incontinence POS N
(any POS N
involuntary POS N
urine POS N
loss) POS N
at POS N
3 POS N
mo POS N
was POS N
75% POS N
and POS N
69% POS N
(p=0.391) POS N
and POS N
at POS N
6 POS N
mo POS N
was POS N
51% POS N
and POS N
43% POS N
(p=0.686). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Urinary POS N
retention POS N
occurred POS N
only POS N
in POS N
one POS N
case POS N
(control POS N
group). POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

The POS N
percentage POS N
of POS N
cases POS N
returning POS N
to POS N
baseline POS N
in POS N
all POS N
QoL POS N
domains POS N
(except POS N
insomnia) POS N
was POS N
similar POS N
at POS N
6 POS N
mo POS N
between POS N
the POS N
two POS N
groups. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

Short POS N
follow-up, POS N
lack POS N
of POS N
blinding, POS N
and POS N
probable POS N
small POS N
differences POS N
in POS N
our POS N
method POS N
of POS N
MFRR POS N
performed POS N
compared POS N
with POS N
other POS N
studies POS N
were POS N
identified POS N
as POS N
significant POS N
limitations. POS N

Posterior POS N
reconstruction POS N
of POS N
the POS N
musculofascial POS N
complex POS N
does POS N
not POS N
appear POS N
to POS N
improve POS N
early POS N
urinary POS N
incontinence POS N
after POS N
RALP. POS N

No POS N
significant POS N
difference POS N
in POS N
any POS N
of POS N
the POS N
analysed POS N
outcome POS N
measures POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
impact POS N
of POS N
prolonged POS N
subclinical POS N
hyperthyroidism POS N
on POS N
quality POS N
of POS N
life POS N
is POS N
unclear. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

After POS N
6 POS N
months, POS N
none POS N
of POS N
the POS N
quality POS N
of POS N
life POS N
parameters POS N
in POS N
the POS N
low-TSH POS N
group POS N
was POS N
different POS N
from POS N
baseline POS N
values. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
the POS N
euthyroid POS N
group, POS N
motivation POS N
was POS N
significantly POS N
improved POS N
(Multidimensional POS N
Fatigue POS N
Index-20, POS N
P POS N
= POS N
0.003), POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

although POS N
this POS N
parameter POS N
did POS N
not POS N
differ POS N
from POS N
the POS N
reference POS N
group POS N
at POS N
baseline. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

A POS N
probable POS N
worsening POS N
in POS N
role POS N
limitations POS N
as POS N
a POS N
result POS N
of POS N
physical POS N
problems POS N
(Short POS N
Form-36; POS N
P POS N
= POS N
0.050) POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

No POS N
improvement POS N
in POS N
the POS N
SDQ POS N
score POS N
was POS N
observed. POS N

Restoration POS N
of POS N
euthyroidism POS N
in POS N
general POS N
does POS N
not POS N
affect POS N
quality POS N
of POS N
life. POS N

In POS N
summary, POS N
quality POS N
of POS N
life POS N
in POS N
patients POS N
with POS N
DTC POS N
and POS N
long-term POS N
subclinical POS N
hyperthyroidism POS N
in POS N
general POS N
is POS N
preserved. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Laparoscopic-assisted POS N
colectomy POS N
(LAC) POS N
has POS N
emerged POS N
as POS N
the POS N
preferred POS N
minimally POS N
invasive POS N
surgical POS N
strategy POS N
for POS N
diseases POS N
of POS N
the POS N
colon. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
safety POS N
and POS N
efficacy POS N
of POS N
LAC POS N
for POS N
colon POS N
cancer POS N
are POS N
unknown, POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

the POS N
nature POS N
and POS N
magnitude POS N
of POS N
any POS N
quality-of-life POS N
(QOL) POS N
benefit POS N
resulting POS N
from POS N
LAC POS N
for POS N
colon POS N
cancer POS N
is POS N
also POS N
unknown. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

In POS N
an POS N
intention-to-treat POS N
analysis POS N
comparing POS N
SDS POS N
pain POS N
intensity, POS N
SDS POS N
summary, POS N
QOL POS N
Index POS N
summary, POS N
and POS N
global POS N
rating POS N
scale POS N
scores POS N
at POS N
each POS N
time POS N
point, POS N
the POS N
only POS N
statistically POS N
significant POS N
difference POS N
observed POS N
between POS N
groups POS N
was POS N
the POS N
global POS N
rating POS N
scale POS N
score POS N
for POS N
2 POS N
weeks POS N
postsurgery. POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

The POS N
mean POS N
(median) POS N
global POS N
rating POS N
scale POS N
scores POS N
for POS N
2 POS N
weeks POS N
postsurgery POS N
were POS N
76.9 POS N
(80) POS N
for POS N
LAC POS N
vs POS N
74.4 POS N
(75) POS N
for POS N
open POS N
colectomy POS N
(P POS N
=.009). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

While POS N
in POS N
the POS N
hospital, POS N
patients POS N
assigned POS N
to POS N
LAC POS N
required POS N
fewer POS N
days POS N
of POS N
both POS N
parenteral POS N
analgesics POS N
compared POS N
with POS N
patients POS N
assigned POS N
to POS N
open POS N
colectomy POS N
(mean POS N
[median], POS N
3.2 POS N
[3] POS N
vs POS N
4.0 POS N
[4] POS N
days; POS N
P<.001) POS N
and POS N
oral POS N
analgesics POS N
(mean POS N
[median], POS N
1.9 POS N
[1] POS N
vs POS N
2.2 POS N
[2] POS N
days; POS N
P POS N
=.03). POS N

Until POS N
ongoing POS N
trials POS N
establish POS N
that POS N
LAC POS N
is POS N
as POS N
effective POS N
as POS N
open POS N
colectomy POS N
in POS N
preventing POS N
recurrence POS N
and POS N
death POS N
from POS N
colon POS N
cancer, POS N
this POS N
procedure POS N
should POS N
not POS N
be POS N
offered POS N
to POS N
patients POS N
with POS N
colon POS N
cancer. POS N

Only POS N
minimal POS N
short-term POS N
QOL POS N
benefits POS N
were POS N
found POS N
with POS N
LAC POS N
for POS N
colon POS N
cancer POS N
compared POS N
with POS N
standard POS N
open POS N
colectomy. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
extent POS N
to POS N
which POS N
chemotherapy POS N
may POS N
relieve POS N
tumour-related POS N
symptoms, POS N
improve POS N
quality POS N
of POS N
life POS N
and POS N
prolong POS N
survival POS N
in POS N
patients POS N
with POS N
gastric POS N
cancer POS N
is POS N
not POS N
known POS N
in POS N
spite POS N
of POS N
the POS N
extensive POS N
use POS N
of POS N
this POS N
treatment POS N
modality. POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

More POS N
patients POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(45%, POS N
14/31) POS N
had POS N
an POS N
improved POS N
or POS N
prolonged POS N
high POS N
quality POS N
of POS N
life POS N
for POS N
a POS N
minimum POS N
period POS N
of POS N
4 POS N
months POS N
compared POS N
to POS N
those POS N
in POS N
the POS N
best POS N
supportive POS N
care POS N
group POS N
(20%, POS N
6/30, POS N
P POS N
< POS N
0.05). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

A POS N
similar POS N
difference POS N
was POS N
seen POS N
in POS N
the POS N
treating POS N
physician's POS N
evaluation POS N
of POS N
whether POS N
the POS N
patient POS N
was POS N
subjectively POS N
improved POS N
or POS N
continued POS N
to POS N
do POS N
well POS N
for POS N
at POS N
least POS N
4 POS N
months POS N
(17/31, POS N
55% POS N
versus POS N
6/30, POS N
20%, POS N
P POS N
< POS N
0.01). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Overall POS N
survival POS N
was POS N
longer POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(median POS N
8 POS N
vs. POS N
5 POS N
months) POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

although POS N
the POS N
difference POS N
was POS N
not POS N
statistically POS N
significant POS N
(P POS N
= POS N
0.12). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

After POS N
corrections POS N
for POS N
imbalances POS N
in POS N
pretreatment POS N
characteristics, POS N
chemotherapy POS N
treatment POS N
was, POS N
however, POS N
associated POS N
with POS N
a POS N
survival POS N
benefit POS N
(P POS N
= POS N
0.003). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

Also, POS N
the POS N
quality-adjusted POS N
survival POS N
time POS N
and POS N
time POS N
to POS N
disease POS N
progression POS N
were POS N
longer POS N
for POS N
patients POS N
randomized POS N
to POS N
chemotherapy POS N
(median POS N
5 POS N
vs. POS N
2 POS N
months, POS N
P POS N
= POS N
0.03). POS N

The POS N
number POS N
of POS N
patients POS N
who POS N
benefit POS N
from POS N
treatment POS N
is, POS N
however, POS N
still POS N
rather POS N
limited. POS N

The POS N
results POS N
show POS N
that POS N
chemotherapy POS N
can POS N
add POS N
to POS N
both POS N
quantity POS N
and POS N
quality POS N
of POS N
life POS N
in POS N
advanced POS N
gastric POS N
cancer. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

In POS N
the POS N
three-group POS N
randomisation, POS N
in POS N
comparison POS N
with POS N
standard POS N
radiotherapy, POS N
median POS N
overall POS N
survival POS N
was POS N
significantly POS N
longer POS N
with POS N
temozolomide POS N
(8·3 POS N
months POS N
[95% POS N
CI POS N
7·1-9·5; POS N
n=93] POS N
vs POS N
6·0 POS N
months POS N
[95% POS N
CI POS N
5·1-6·8; POS N
n=100], POS N
hazard POS N
ratio POS N
[HR] POS N
0·70; POS N
95% POS N
CI POS N
0·52-0·93, POS N
p=0·01), POS N
but POS N
not POS N
with POS N
hypofractionated POS N
radiotherapy POS N
(7·5 POS N
months POS N
[6·5-8·6; POS N
n=98], POS N
HR POS N
0·85 POS N
[0·64-1·12], POS N
p=0·24). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
all POS N
patients POS N
who POS N
received POS N
temozolomide POS N
or POS N
hypofractionated POS N
radiotherapy POS N
(n=242) POS N
overall POS N
survival POS N
was POS N
similar POS N
(8·4 POS N
months POS N
[7·3-9·4; POS N
n=119] POS N
vs POS N
7·4 POS N
months POS N
[6·4-8·4; POS N
n=123]; POS N
HR POS N
0·82, POS N
95% POS N
CI POS N
0·63-1·06; POS N
p=0·12). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

For POS N
age POS N
older POS N
than POS N
70 POS N
years, POS N
survival POS N
was POS N
better POS N
with POS N
temozolomide POS N
and POS N
with POS N
hypofractionated POS N
radiotherapy POS N
than POS N
with POS N
standard POS N
radiotherapy POS N
(HR POS N
for POS N
temozolomide POS N
vs POS N
standard POS N
radiotherapy POS N
0·35 POS N
[0·21-0·56], POS N
p<0·0001; POS N
HR POS N
for POS N
hypofractionated POS N
vs POS N
standard POS N
radiotherapy POS N
0·59 POS N
[95% POS N
CI POS N
0·37-0·93], POS N
p=0·02). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Patients POS N
treated POS N
with POS N
temozolomide POS N
who POS N
had POS N
tumour POS N
MGMT POS N
promoter POS N
methylation POS N
had POS N
significantly POS N
longer POS N
survival POS N
than POS N
those POS N
without POS N
MGMT POS N
promoter POS N
methylation POS N
(9·7 POS N
months POS N
[95% POS N
CI POS N
8·0-11·4] POS N
vs POS N
6·8 POS N
months POS N
[5·9-7·7]; POS N
HR POS N
0·56 POS N
[95% POS N
CI POS N
0·34-0·93], POS N
p=0·02), POS N
but POS N
no POS N
difference POS N
was POS N
noted POS N
between POS N
those POS N
with POS N
methylated POS N
and POS N
unmethylated POS N
MGMT POS N
promoter POS N
treated POS N
with POS N
radiotherapy POS N
(HR POS N
0·97 POS N
[95% POS N
CI POS N
0·69-1·38]; POS N
p=0·81). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

the POS N
most POS N
common POS N
grade POS N
3-4 POS N
adverse POS N
events POS N
in POS N
the POS N
temozolomide POS N
group POS N
were POS N
neutropenia POS N
(n=12) POS N
and POS N
thrombocytopenia POS N
(n=18). POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Grade POS N
3-5 POS N
infections POS N
in POS N
all POS N
randomisation POS N
groups POS N
were POS N
reported POS N
in POS N
18 POS N
patients. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Two POS N
patients POS N
had POS N
fatal POS N
infections POS N
(one POS N
in POS N
the POS N
temozolomide POS N
group POS N
and POS N
one POS N
in POS N
the POS N
standard POS N
radiotherapy POS N
group) POS N
and POS N
one POS N
in POS N
the POS N
temozolomide POS N
group POS N
with POS N
grade POS N
2 POS N
thrombocytopenia POS N
died POS N
from POS N
complications POS N
after POS N
surgery POS N
for POS N
a POS N
gastrointestinal POS N
bleed. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Standard POS N
radiotherapy POS N
was POS N
associated POS N
with POS N
poor POS N
outcomes, POS N
especially POS N
in POS N
patients POS N
older POS N
than POS N
70 POS N
years. POS N

MGMT POS N
promoter POS N
methylation POS N
status POS N
might POS N
be POS N
a POS N
useful POS N
predictive POS N
marker POS N
for POS N
benefit POS N
from POS N
temozolomide. POS N

Both POS N
temozolomide POS N
and POS N
hypofractionated POS N
radiotherapy POS N
should POS N
be POS N
considered POS N
as POS N
standard POS N
treatment POS N
options POS N
in POS N
elderly POS N
patients POS N
with POS N
glioblastoma. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

The POS N
response POS N
rate POS N
was POS N
35.7% POS N
vs. POS N
43.8% POS N
(P POS N
= POS N
0.4), POS N
median POS N
TTP POS N
was POS N
4.7 POS N
months POS N
vs. POS N
5.5 POS N
months POS N
(P POS N
= POS N
0.6), POS N
one-year POS N
survival POS N
rate POS N
was POS N
38.5% POS N
vs. POS N
58.6% POS N
(P POS N
= POS N
0.07) POS N
in POS N
the POS N
NL POS N
and POS N
NP POS N
groups, POS N
respectively. POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

Grade POS N
I-II POS N
neuro-sensory POS N
toxicity POS N
occurred POS N
significantly POS N
more POS N
frequent POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(68.4% POS N
vs. POS N
36.4%, POS N
P POS N
= POS N
0.0017). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

However, POS N
Grade POS N
I-II POS N
granulocytopenia POS N
was POS N
significantly POS N
less POS N
occurred POS N
in POS N
NL POS N
group POS N
than POS N
in POS N
NP POS N
group POS N
(49.4% POS N
vs. POS N
70.6%, POS N
P POS N
= POS N
0.037). POS N

Due POS N
to POS N
good POS N
efficacy POS N
and POS N
tolerability, POS N
the POS N
NL POS N
regimen POS N
offered POS N
a POS N
new POS N
candidate POS N
for POS N
treating POS N
advanced POS N
NSCLC. POS N

There POS N
was POS N
no POS N
statistically POS N
difference POS N
between POS N
the POS N
two POS N
groups POS N
regarding POS N
quality POS N
of POS N
life. POS N

